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Abstract
Background
Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) is emerging as an
important subtype of lung cancer comprising 15-20%of non-squamous tumours. This subtype is more common in women
than men, is less associated with smoking and has an improved prognosis compared to the M- subtypes.
Objectives
To assess the clinical effectiveness of single or combination EGFR therapies used in the first-line treatment of patients with
locally advanced or metastatic EGFR M+ NSCLC compared with other cytotoxic chemotherapy (CTX) agents, or best
supportive care (BSC). The primary outcome is overall survival.
Search methods
We conducted electronic searches of the databases of The Cochrane Library (to 1st June 2015), MEDLINE (1946 to 1st
June 2015), EMBASE (1980 to 1st June 2015), ISI Web of Science (1899 to 1st June 2015). In addition we searched the
conference abstracts of ASCO and ESMO. Evidence Review Group submissions to NICE were also searched as were the
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references lists of retrieved articles.
Selection criteria
Parallel randomised controlled trials comparing EGFR-targeted agents (alone or in combination with cytotoxic agents or
BSC) with cytotoxic chemotherapy (single or doublet) or best supportive care (BSC) in chemotherapy-naive patients with
locally advanced or metastatic (Stage IIIB or IV) EGFR M+ NSCLC unsuitable for treatment with curative intent.
Data collection and analysis
Two authors independently identified articles, extracted data and carried out risk of bias assessments. Meta-analyses were
conducted using a fixed effect model unless there was substantial heterogeneity when a random effects analysis was also
performed as a sensitivity analysis.
Main results
Nineteen trials met the inclusion criteria. Seven of these exclusively recruited patients with EGFR M+ NSCLC, the remainder
recruited a mixed population and report results for patients with EGFR M+ NSCLC as subgroup analyses. The number of
patients with EGFR M+ tumours totalled 2317 of whom 1700 were of Asian origin.
Erlotinib was the intervention treatment in 8 trials, gefitinib in 7 trials, afatinib in 2 trials and cetuximab in 2 trials. Overall
survival (OS) data showed inconsistent results between the included trials that compared EGFR targeted treatments against
CTX or placebo. The findings of one trial (FASTACT 2) did report a statistically significant OS gain for patients treated with
erlotinib plus CTX when compared to CTX alone but this result was based on a small number of patients (n=97). For
progression-free survival (PFS), a pooled analysis of three trials (n=378) demonstrated a statistically significant benefit for
erlotinib compared with CTX (HR=0.30; 95% CI: 0.23 to 0.40).
In a pooled analysis with 491 patients with gefitinib, two trials (IPASS; NEJSG) demonstrated a statistically significant PFS
benefit of gefitinib compared with CTX (HR=0.39; 95% CI:0.32 to 0.48).
Afatinib (n=709) showed a statistically significant benefit when compared with chemotherapy in a pooled analysis of two trials
(HR= 0.42; 95% CI: 0.34 to 0.53). Commonly reported adverse events for afatinib, erlotinib and gefitinib monotherapy were
rash and diarrhoea.
No statistically significant PFS benefit for cetuximab plus CTX (n=81) compared to chemotherapy alone was reported in
either of the two trials.
Six trials reported on quality of life and symptom improvement using different methodologies. For each of erlotinib, gefitinib
and afatinib, two trials showed improvement in one or more indices for the TKI compared to chemotherapy.
The risk of bias was mixed, with lack of blinding being the main reason the majority of trial were classified as at unclear risk
of bias.
Authors' conclusions
Erlotinib, gefitinib or afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased response rate
and prolonged progression-free survival compared to cytotoxic chemotherapy . Cytotoxic chemotherapy is less effective in
this subtype than erlotinib, gefitinib or afatinib and is associated with greater toxicity. There is no data supporting monoclonal
antibody therapy.
Plain language summary
First-line treatment of advanced non-small cell lung cancer that is identified as being EGFR mutation positive.
Background
Lung cancer is the most common cancer in the world. It tends to be diagnosed in older people and because it is has few
symptoms is usually diagnosed at a late stage of the disease.
The most common type of lung cancer is non-small cell lung (NSCLC) cancer which affects specific cells in the lungs. Around
15-20% of people with NSCLC will have a specific type of disease known as epidermal growth factor receptor positive
(EGFR M+) . People who have EGFR M+ NSCLC usually do not respond to standard treatment with chemotherapy. New
treatments which can target EGFR M+ NSCLC have recently been developed and licensed and their efficacy is assessed in
this review.
Objectives
The purpose of this review is to assess whether treatments targeted at EGFR M+ NSCLC have any benefit in survival or
quality of life compared to standard chemotherapy.
Trial Characteristics
We identified 19 trials that investigated four different EGFR-targeted drugs, comprising the tyrosine kinase inhibitors afatinib,
erlotinib and gefitinib, and the antibody cetuximab. Trials which presented results up to June 2015 are included in this review.
Results
This review demonstrates that treatment with erlotinib, gefitinib and afatinib leads to increased time until disease progression
compared to conventional or combined chemotherapy. However, there is no increase in overall survival when compared with
standard chemotherapy except for one preplanned subgroup analysis for afatinib in patients with the codon 19 deletion.
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There was no increase in delayed disease progression or survival when cetuximab is compared with standard
chemotherapy.
Conclusion
Treatment with erlotinib, gefitinib and afatinib confer delayed disease progression but do not extend life. The side effects
associated with erlotinib, gefitinib and afatinib are more favourable than those associated with conventional chemotherapy.
Treatment with cetuximab in combination with chemotherapy is of no benefit in controlling these tumours or extending life.
Background 
Description of the condition
Lung cancer is the most common cancer in the world and the second most common cancer diagnosed in the UK (Cancer
Research UK). Globally, in 2012, 1.8 million people were diagnosed with lung cancer, representing 12.9% of all cancers (
GLOBOCAN 2012). In the UK in 2012 45,000 new cases of lung cancer were diagnosed, 13% of all new cancers (Cancer
Research UK 2012b). Lung cancer is rarely diagnosed in people younger than 40 years of age and 90% of cases are
identified in people over the age of 60 years (Cancer Research UK 2013). In both men and women, smoking is the primary
cause of lung cancer (Cancer Research UK 2013). Prognosis is poor as early stage lung cancer is often asymptomatic, and
the majority of patients are diagnosed at a late stage. (Cancer Research UK 2012b). In the UK in 2012, 35,000 people died
of lung cancer, representing 22% of all deaths from cancer in the UK (Cancer Research UK 2012a).
Non-small cell lung cancer (NSCLC) accounts for approximately 84% of lung cancer cases and comprises two main
histological subgroups, squamous cell carcinoma and non-squamous cell carcinoma (Schiller 2002). Squamous cell
carcinoma accounts for 33% of all NSCLC cases whilst non-squamous cell carcinoma (including adenocarcinoma and large
cell carcinoma) accounts for 29% of NSCLC cases. Approximately 16% of patients have NSCLC that is ‘not-otherwise
specified’ with the diagnosis based on cytology alone (Schiller 2002). The prognosis for patients with metastatic NSCLC is
poor, with a median survival of the order of 11 months (Schiller 2002).
Treatment for patients with NSCLC is dependent not only on the histological subtype and genetic subtype of the patient, but
also on disease stage, co-morbidity, and performance status (PS). Chemotherapy for advanced disease can extend overall
survival (OS) by several months compared to best supportive care (BSC) and may improve quality of life (QoL), but it may
not be appropriate for many patients with poor PS (Spiro 2004;Brown 2013).
In recent years the clinical subtypes of NSCLC have become relevant to the selection of treatment regimens. Attention has
been drawn to tumours that harbour the epidermal growth factor receptor mutation (EGFR M+). The EGFR, a protein located
on the cell surface, binds to and activates epidermal growth factor. This binding induces receptor dimerization and tyrosine
kinase autophosphorylation, leading through signal transduction to cell proliferation (NCBI: Han 2012). It is estimated that
10% to 15% of patients with non-squamous NSCLC have tumours that are EGFR M+ (Peters 2012; Rosell 2012). An EGFR
mutation frequency of 21% was reported by Shigematsu 2005 and is more frequently observed in never smokers than ever
smokers (51% vs 10%), in adenocarcinomas vs cancers of other histologies (40% vs 3%), in patients of East Asian ethnicity
vs other ethnicities (30% vs 8%), and in females vs males (42% vs 14%). Other trials have reported EGFR mutations (exons
18 to 21) in 17% to 20% of samples of NSCLC (Rosell 2009; Ulivi 2012) and these more frequently occur in never smoking
females (Scoccianti 2012).
The identification of patients with EGFR M+ tumours has led to the development of targeted therapies comprising small
molecule tyrosine kinase inhibitors (TKIs) directed at the signal transduction pathway between the cell membrane and the
nucleus, while monoclonal antibodies (MABs) bind to and inactivate the receptor on the cell membrane. The TKIs are orally
administered agents while the MABs are given intravenously. Patients of interest to this review are chemotherapy-naive
patients with locally advanced or metastatic (Stage IIIB or IV) EGFR M+ NSCLC who are not suitable for treatment with
curative intent, such as surgery or radical radiotherapy.
Description of the intervention
In Europe, there are three licensed treatments that target EGFR M+ NSCLC, afatinib, erlotinib and gefitinib.These drugs are
TKIs of EGFR and target proteins on the cancer cells related to activation of the signal transduction pathway. They are oral
treatments (tablets) that are taken daily until the disease progresses. Other drugs, for example, the TKI dacomitinib and the
MAB cetuximab, are therapies currently under clinical investigation but are not yet licensed for the first-line treatment of
patients with EGFR M+ NSCLC.
In the UK, NICE has recommended the use of monotherapy erlotinib (NICE 2012), monotherapy gefitinib (NICE 2010) and
more recently, monotherapy afatinib (NICE 2014) for the first-line treatment of EGFR M+ NSCLC. In Europe, European
Society for Medical Oncology (ESMO) guidelines recommend first-line treatment with monotherapy afatinib, erlotinib or
gefitinib (Peters 2012; Reck 2014). In the USA, the Food and Drug Administration (FDA) has approved the use of
monotherapy erlotinib and monotherapy afatinib (FDA 2013;FDA 2014). Globally there is considerable variation in the use of
each of these drugs to treat patients with NSCLC, and the availability and quality control of mutation testing which
determines patient selection.
Why it is important to do this review
Treatments for patients with NSCLC are evolving rapidly. Up until early 2000, patients with NSCLC were offered standard
cytotoxic chemotherapy treatments (for example, docetaxel, vinorelbine, paclitaxel and gemcitabine), and in many cases
given in two-drug combinations (Brown 2013). However, in recent years patients have been treated with drugs according to
their disease histology (for example, pemetrexed for non-squamous disease). Even more recently, as understanding of
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NSCLC has evolved, targeted treatments have been developed (for example,TKIs and MABs) to treat specific groups of
patients based on molecular criteria. It is estimated that around 10% (n = 4000 annually) of all lung cancer patients in the UK
have locally advanced or metastatic EGFR M+ NSCLC (NICE 2010), but the prevalence is higher in Asian populations. It is,
therefore, important to synthesise evidence for the clinical effectiveness and toxicity of these innovative treatments to ensure
that patients are being treated with the most clinically effective drugs for their specific disease subtype.
Objectives 
To assess the clinical effectiveness of single or combination EGFR therapies used in the first-line treatment of patients with
locally advanced or metastatic EGFR M+ NSCLC compared with other cytotoxic chemotherapy (CTX) agents used alone or
in combination, or best supportive care (BSC). The primary outcome is overall survival.
Methods 
Criteria for considering studies for this review 
Types of studies 
Parallel randomised controlled trials (RCTs)
Types of participants 
Chemotherapy-naive patients with locally advanced or metastatic (Stage IIIB or IV) EGFR M+ NSCLC unsuitable for
treatment with curative intent, such as surgery or radical radiotherapy.
Types of interventions 
EGFR M+ targeted agents, alone or in combination with cytotoxic agents, compared with cytotoxic agents used alone or in
combination or BSC.
We excluded trials comparing single agents or combinations of cytotoxic chemotherapy without a targeted therapy in either
arm, trials with targeted therapy in both arms and we did not evaluate maintenance or second-line strategies.
Types of outcome measures 
Primary outcomes
Overall survival (OS)
Secondary outcomes
Progression-free survival (PFS)
Tumour response
Toxicity and adverse effects (AEs) of treatment
Quality of life (QoL) (e.g. Functional Assessment of Cancer Therapy - Lung (FACT-L) and Trial Outcome Index (TOI))
Symptom palliation
Search methods for identification of studies 
Electronic searches 
We searched the following electronic databases for relevant published literature up to June 2015. Searches were not
restricted by language.
CENTRAL (Cochrane Central Register of Controlled Trials) (The Cochrane Library). June 2015
CDSR (Cochrane Database of Systematic Reviews). June 2015
DARE (Database of Abstracts of Reviews of Effectiveness).June 2015
EMBASE (OvidSP). June 2015
Health Technology Assessment (HTA) database.June 2015
ISI Web of Science - Proceedings (Index to Scientific & Technical Proceedings).June 2015
MEDLINE (accessed via PubMed and OvidSP). June 2015
ISI Web of Science - Science Citation Index Expanded.June 2015
We modified the search strategies over time. To ensure the integrity of the searches, the strategy outlined in Appendix 3 was
re-run in PubMed from inception to June 2015 (overall) and we compared the results with the results of all other searches.
Any non-duplicate articles were examined for possible inclusion in the review. The strategies used to explore MEDLINE (via
Ovid) are outlined in Appendix 1; Appendix 2; Appendix 3 and we adapted these, as appropriate, for the remaining
databases.
Searching other resources 
Other resources we searched included: bibliographies of identified sources and use of Evidence Review Group (ERG)
reports to the National Institute for Health and Care Excellence. We searched the proceedings of relevant conferences such
as the American Society for Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) up to June
2015. If data were available, we considered including them in the review.
We developed a database of relevant references using EndNote X5 software.
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Data collection and analysis 
Selection of studies 
Two review authors independently took part in all stages of trial selection (FV and VB Search 1; VB and JG Search 2, JAG
and YD, JAG and JG Search 3). Firstly, review authors independently scanned the titles and abstracts of references
identified by the search strategy. Full details of possibly relevant trials were obtained and assessed independently for
inclusion in the review. If a disagreement occurred, the review authors attempted to reach a consensus by discussion, or by
involving a third review author (AB and JG). Trials that did not meet all of the inclusion criteria were excluded and their
bibliographic details listed with reasons for exclusion. Ongoing trials that did not report relevant data but met the inclusion
criteria were listed for future use. For trials published in abstract form only, if it was clear that a trial was eligible then it was
included. If it was not clear, authors were contacted for further information and the trial was placed in ‘awaiting assessment’
until a reply was received.
Data extraction and management 
Two review authors carried out the data extraction (FV and VB Search 1; VB and JG Search 2, JAG and JG Search 3) using
pre-tested data extraction forms and a third review author (KD) independently checked for the extracted data for accuracy.
We extracted data relating to the outcome measures as well as information on trial design and participants (for example,
baseline characteristics). Where data from trials were presented in multiple publications we extracted and reported these as
a single trial with all other relevant publications listed.
Assessment of risk of bias in included studies
We assessed each included trial for risk of bias using criteria outlined in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) (see domains listed below) Two reviewers (FV and JG Search 1; JG and KD Search
2) independently carried out the assessments. Any disagreements were resolved through discussion.
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective outcome reporting (reporting bias).
7. Any other identified bias, including inappropriate influence of funders.
We report bias as either high, low or unclear (further details of reporting bias are outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We assessed the domains of blinding and incomplete outcome data at
the outcome level.
Summary of findings tables are presented with each outcome graded accordingly using the GRADE approach (GRADE
Working Group 2004).
Measures of treatment effect
For binary outcomes, where sufficient data were available, we present relative treatment effects in the form of relative risks
(RR) with 95% confidence intervals (CI). For continuous outcomes, we calculated mean differences (MD) and 95% CIs
provided there was no evidence that the data were subject to skew. If statistical tests used in the original paper were for
skewed data, or if median and interquartile ranges were reported, we assumed the data were skewed.¬Standardised mean
differences (SMDs) were calculated for QoL variables where appropriate. For time to event outcomes, we extracted log
hazard ratios (log HR) when available, with 95% CI. If the log HR was not reported, data were requested from authors.
All trials allowed patient crossover to another treatment after progression but there are no details regarding how this was
dealt with in any of the analyses of OS.
We considered trials that: (1) provided only unplanned, interim findings, and (2) were continuing to recruit patients for
inclusion in the review but we did not not include these in the meta-analysis.
Unit of analysis issues 
We did not include cross-over trials in the review.
Dealing with missing data
We contacted authors (and sponsors) of trials for missing data.
Assessment of heterogeneity 
We assessed statistical heterogeneity between trials visually by inspection of the forest plots and using the Chi2 test (p < 0.1
was considered significant due to the low power of the test). We also calculated the I2 statistic;, this describes the percentage
of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). Values of I2 range from 0
to 100, with 0 representing no heterogeneity and 100 representing considerable heterogeneity.
For this review:
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0% to 40%, heterogeneity might not be important;
30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity and
75% to 100%, considerable heterogeneity.
Assessment of reporting biases
If a sufficient number of trials are identified, a funnel plot can be constructed. If asymmetry is present in the funnel plot,
possible causes of bias may be explored, such as heterogeneity or outcome reporting bias.
Data synthesis
We have summarised individual trial data in structured tables and as a narrative description. We combined data for time to
event outcomes using the generic inverse variance method. We used the Mantel-Haenszel method for dichotomous
outcomes. In future versions of this review where data are available, we may combine continuous outcomes using the
inverse variance method.
We conducted meta-analyses using the fixed-effect model unless there was substantial heterogeneity (I2 > 50%) and used a
random-effect model as a sensitivity analysis. In future versions of this review, if there is considerable heterogeneity (I2 >
75%) we may combine data but conclusions will highlight the amount of heterogeneity present.
Indirect comparisons and network meta-analysis
In future versions of this review, if trials are identified that compare different interventions which are sufficiently similar in
terms of their populations and outcomes, we may make indirect comparisons for competing interventions that have not been
compared directly. Do we not need to be more specific about why we didn't do this while others have! Multiple treatment
meta-analysis (also referred to as network meta-analysis) may combine direct and indirect comparisons using multivariate
meta-analysis as this will also take into account any multi-arm trials. We will use a random-effect model within STATA to
conduct analyses using code from www.mtm.uoi.gr.
Transitivity (the trials making different direct comparisons must be sufficiently similar in all respects other than the treatments
being compared) will be evaluated clinically.¬We will compare the distributions of possible effect modifiers (smoking status;
age, gender, ethnicity and performance status) across comparisons using subgroup analysis. As the review is only
considering first-line treatment, indications are similar.
Consistency will be evaluated using a loop specific approach (Salanti 2009) and design interaction consistency model (
Higgins 2012) will also be used. If inconsistency is identified, the network meta-analysis will not be presented.
Estimates of treatment effect will be assessed by pairwise meta-analysis. Network meta-analysis will be conducted where
appropriate.
Prior to analysis a diagram of the network for all relevant interventions will be drawn, indicating the number of trials per
comparison. Ranking probabilities for each treatment will be derived and displayed using the Surface Under the Cumulative
RAnking curve (SUCRA) plot and rankograms (Salanti 2011).
The possible effects of risk of bias on the clinical effectiveness data and review findings will be discussed.
Subgroup analysis and investigation of heterogeneity 
In an update of this review, when sufficient trials are included and where data are available, subgroup analysis may be
performed for the following subgroups:
Smoking status: smoker, non-smoker;
Age: < 65 years, age ≥ 65 years;
Gender: male, female;
Ethnicity: Asian, non-Asian;
Performance status:0/1, 2/3.
Sensitivity analysis
In an update of this review, when sufficient srials are included, we will conduct sensitivity analyses based on the overall risk
of bias of the included trials. Overall risk of bias will be based on sequence generation, allocation concealment and blinding
(for the specific outcome), and the summary assessment will be based on recommendations in Table 8.7a of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Results 
Description of studies 
Results of the search
The database search strategy yielded 7674 non-duplicate papers. Of these we screened 336 full text records for inclusion in
the review. We identified a further 7 records via hand-searching of reference lists and we found 2 other records from our
search of conference abstracts. All of the potentially relevant references were screened and we included 19 eligible RCTs
(reported in 55 publications) comparing EGFR targeted therapy to chemotherapy as first-line treatment in NSCLC patients in
our review (Figure 1).
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Three trials are classified as awaiting assessment (TALENT; TRIBUTE; INSPIRE) and are not yet included in the review. We
contacted the authors of TALENT; TRIBUTE and asked them to provide data on the EGFR M+ population. We have not
received a response. We await the publication of the outcomes for the EGFR M+ subgroup from INSPIRE . There is one
ongoing trial (ARCHER).
Included studies
The 19 trials (Characteristics of included studies) which met the inclusion criteria (BMSO99; CHEN;ENSURE EURTAC;
FASTACT 2; First-SIGNAL; FLEX; GTOWG; INTACT 1; INTACT 2; IPASS; LUX-Lung 3; LUX-Lung 6; NEJSG; OPTIMAL;
TOPICAL; TORCH; WJTOG3405; Yu 2014) were published or updated between 2003 and 2015. With the exception of
GTOWG, all trials were published as peer-reviewed papers. The overall number of patients recruited to the trials ranged
between 113 (CHEN) and 1217 (IPASS) with an overall trial population of 9414. The median length of follow up (where
reported) ranged from 15.9 months (INTACT 1) to 59 months (WJTOG3405).
EGFR mutation status - overall population versus subgroups
Seven trials included EGFR M+ patients only (EURTAC; ENSURE; LUX-Lung 3; LUX-Lung 6; NEJSG; OPTIMAL;
WJTOG3405). The number of patients recruited to the EGFR M+ only trials ranged from 165 (OPTIMAL) to 364 (LUX-Lung 6
) with a total population of 1672. The remaining 12 trials recruited a 'mixed' population of patients, that is patients were not
selected for inclusion in the trial on the basis of their EGFR mutation status. These latter trials report results for the subgroup
of patients with EGFR M+ mutation status only. The numbers of patients reported in these subgroups range from 10 (
GTOWG) to 261(IPASS) with a combined total of 645. The combined total of patients with EGFR M+ NSCLC is 2317.
Three trials were conducted exclusively in Europe (EURTAC; GTOWG; TOPICAL), 10 were conducted exclusively in Asia (
CHEN; ENSURE; FASTACT 2; First-SIGNAL; IPASS; LUX-Lung 6 NEJSG; OPTIMAL; WJTOG3405; Yu 2014) and the
remainder were conduced in America (BMSO99), Italy and Canada (TORCH), America and Europe (INTACT 2). LUX-Lung 3
, INTACT 1 and FLEX were international trials. The seven trials that recruited exclusively EGFR M+ patients were conducted
in Asia (ENSURE; LUX-Lung 6; NEJSG; OPTIMAL; WJTOG3405) and Europe (EURTAC) with one international trial (LUX-
Lung 3).
Four of the trials were placebo controlled and double-blinded (FASTACT 2; INTACT 1; INTACT 2; TOPICAL) the remainder
were specifically reported as being open-label or did not report blinding status. In the latter case, we assumed these to be
open-label due to the nature of the interventions and comparator (i.e. oral vs i.v. treatments). Three of the 19 included trials
were phase II (CHEN; GTOWG; Yu 2014) whilst the others were phase III. Fifteen of the 19 trials (BMSO99; CHEN;
ENSURE; EURTAC; FASTACT 2, First-SIGNAL; FLEX; INTACT 1; INTACT 2; IPASS; OPTIMAL; TOPICAL; TORCH; LUX-
Lung 3; LUX-Lung 6) were partially or totally funded by a pharmaceutical company; the NEJSG and WJTOG3405 trials were
funded by scientific groups. The funding source for the GTOWG and Yu 2014 trials is not reported.
Population characteristics
Data for age, sex, performance status (PS) and smoking status were provided for all trials except for the INTACT 1, INTACT
2 and GTOWG trials (no details of smoking history). The median age of the overall population of all the patients in the
included trials ranged from 56 to 77 years; the median age of patients in the EGFR M+ only trials ranged from 56 to 65 years.
Two trials (CHEN and GTOWG) only included patients aged over 70 years and NEJSG and Yu 2014 only reported mean
age. There was a greater proportion of females in 9 of the trials (ENSURE; First-SIGNAL; IPASS; LUX-Lung 3; LUX-Lung 6;
NEJSG; OPTIMAL; WJTOG3405; EURTAC), and greater prevalence of males in 7 trials (TORCH; CHEN; BMSO99;
GTOWG; INTACT 1; INTACT 2 FLEX). The majority of patients were of good PS (ECOG or WHO 0 or 1). The GTOWG
abstract did not report PS.
It is notable that in all of the trials that recruited EGFR M+ patients only, the proportion of females was greater than males
ENSURE; EURTAC; LUX-Lung 3; LUX-Lung 6; NEJSG; OPTIMAL; WJTOG3405.
Interventions
Erlotinib
Eight trials used erlotinib (n= 754 EGFR M+) as the EGFR targeted therapy (CHEN; ENSURE; EURTAC; FASTACT 2;
GTOWG; OPTIMAL; TOPICAL; TORCH). In FASTACT 2, erlotinib was used in combination with a platinum doublet
containing gemcitabine.
Gefitinib
Seven trials used gefitinib (n=773 EGFR M+) as the EGFR targeted therapy (First-SIGNAL; INTACT 1; INTACT 2; IPASS;
NEJSG; WJTOG3405; Yu 2014). In INTACT 1; INTACT 2; Yu 2014 gefitinib was used in combination with chemotherapy.
Afatinib
Two trials compared afatinib (n=709) with cytotoxic chemotherapy (LUX-Lung 3;LUX-Lung 6).
Cetuximab
Two trials (n=81) compared cetuximab plus chemotherapy with combination chemotherapy (FLEX; BMSO99).
Of the six trials that recruited only patients with EGFR M+ NSCLC, two trials used afatinib (LUX-Lung 3; LUX-Lung 6), two
used erlotinib (EURTAC; OPTIMAL) and two used gefitinib (NEJSG; WJTOG3405). All six EGFR M+ only trials compared
targeted treatment with cytotoxic chemotherapy (EURTAC; LUX-Lung 3; LUX-Lung 6; NEJSG; OPTIMAL; WJTOG3405).
Outcomes
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The primary outcome for the majority of trials was progression-free survival (PFS) with secondary outcomes of overall
survival (OS), tumour response rate, symptom palliation, quality of life (Qol) and safety. Overall survival was the primary
outcome in 6 trials (First-SIGNAL; FLEX; INTACT 1; INTACT 2; TOPICAL; TORCH).
Excluded studies
We excluded 290 records after the selection procedure (Figure 1). The main reasons for exclusion were the use of non-
randomised designs (including systematic reviews and reports from conferences), non-assessment of participants' EGFR
mutation status and non-administration of treatments as first-line therapy. Other trials were excluded if they were designed to
assess maintenance treatment or an EGFR- targeted therapy was used in by trial arms. We were not able to easily exclude
articles at the screening stage as we could not be certain from the abstract whether subgroup analyses of outcomes of
patients with EGFR M+ tumours were reported. In the Characteristics of excluded studies table we list trials that appear to
meet the inclusion criteria, but on closer examination were not a complete match. Patients in 5 trials were not tested for
EGFR mutations Crino 2008; ECOG 4508; Gatzemeier 2003; Goss 2009; Lilenbaum 2008, Two trials tested for EGFR
expression only Rosell 2008;Thatcher 2014. In 3 trials there were too few patients with EGFR M+ tumours to warrant
analysis FASTACT; Heigener 2014; White and in 8 trials TKI treatment was included in both trial arms Hirsh 2011; Janne
2012; JO25567; Massuti 2014; NEJ005 2014; NEJ009; Xie 2015; Yang 2015. One trial assessed the outcomes only of
patients who survived at 1 year Boutsikou 2013 and in another trial there were insufficient samples available for testing
ECOG 4508.
Risk of bias in included studies 
Allocation (selection bias)
Of the 19 included trials, 11 reported adequate information about the methods used to generate the randomisation sequence
and the allocation concealment procedure and these trials were considered to be at low risk of bias (EURTAC; FASTACT 2;
FLEX; IPASS; LUX-Lung 3; LUX-Lung 6; TOPICAL; NEJSG; OPTIMAL; TORCH; WJTOG3405). For the remaining 8 trials,
the risk of bias was considered to be unclear due to the lack of reported information (BMSO99; CHEN; ENSURE; First-
SIGNAL; GTOWG; INTACT 1; INTACT 2; Yu 2014).
Blinding (performance bias and detection bias)
Performance bias
Only 4 of the 19 included trials reported employing blinding procedures (INTACT 1; INTACT 2; NEJSG; TOPICAL). The
remainder were explicitly stated as being open-label or did not report blinding status. In the latter case, we assumed these
trials were open-label due to the differences between interventions and comparator (i.e. oral vs intravenous).
Detection bias
Eleven of the trials were considered to be at low risk of detection bias for the outcome of PFS as they incorporated
independent verification procedures (EURTAC; ENSURE; FASTACT 2 First-SIGNAL; NEJSG; BMSO99; LUX-Lung 3;LUX-
Lung 6) or blinded outcome assessment (INTACT 1; INTACT 2;TOPICAL). None of the remaining trials reported any
independent assessment procedures and were considered to be at high risk of bias for the outcome of PFS.
Incomplete outcome data (attrition bias)
In all trials, all patients were accounted for in the analyses. There did not appear to be any major imbalances in drop-out
rates between trial arms in any of the trials and therefore all trials were considered to be at low risk of bias.
Selective reporting (reporting bias)
Only one trial was considered to be at high risk of reporting bias (CHEN). The trial protocol stated time to progression as a
primary outcome of the trial; however this outcome is not reported in the published paper. Two trials were considered to be at
unclear risk of bias as there was insufficient information available to judge selective reporting (FLEX; GTOWG). All other
trials were considered to be at a low risk of bias as either trial protocols were available or all outcomes stated in the methods
section of the papers were reported.
Other potential sources of bias
Fifteen trials were sponsored fully or in part by pharmaceutical companies. One trial (TORCH) was terminated early as the
non-inferiority of the intervention arm was demonstrated by the first planned interim analysis. Two trials were terminated
early for benefit (ENSURE; EURTAC).
Effects of interventions 
Pairwise meta-analysis
Erlotinib vs Control-
Erlotinib vs gemcitabine plus carboplatin: One trial considered this comparison (OPTIMAL).
Erlotinib vs gemcitabine plus cisplatin: Two trials considered this comparison (ENSURE ; TORCH).
Erlotinib vs docetaxel plus cisplatin or gemcitabine plus cisplatin: One trial considered this comparison (EURTAC).
Erlotinib vs carboplatin plus vinorelbine: One trial considered this comparison (GTOWG).
Erlotinib vs vinorelbine: One trial considered this comparison (CHEN).
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Erlotinib plus gemcitabine plus carboplatin or cisplatin vs gemcitabine plus carboplatin or cisplatin plus placebo: One trial
considered this comparison (FASTACT 2).
Erlotinib vs placebo: One trial considered this comparison (TOPICAL).
Primary outcome: Overall survival
Data from five trials were available for OS (EURTAC; TORCH; CHEN; FASTACT 2; ENSURE). Three trials presented limited
data (OPTIMAL; TOPICAL) and in one trial no data were presented (GTOWG).
The pooled treatment effect estimate for three trials, (HR of 0.95 (95% CI: 0.65, 1.66, I2=0, 3 trials)indicated no significant
difference in OS between the groups ( EURTAC;TORCH; ENSURE). CHEN reported a HR of 2.16 (95% CI: 0.58, 8.10) for
OS comparing erlotinib vs vinorelbine in elderly patients, indicating no significant difference in OS between the groups.
FASTACT 2 reported a HR of 0.48 (95% CI: 0.27, 0.85) for OS indicating a significant difference in OS favouring erlotinib
plus CTX in a trial of 91 patients (Analysis 1.1).
OPTIMAL reported that OS did not differ significantly between the two treatment arms (HR=1.065, p=0.6849). No standard
error was reported so the results can not be entered into a meta-analysis one of the SRs has a correction for this using an
assumption  JAG .
The median overall survival was reported for TOPICAL which was 10.4 months (95% CI 5.5, 15.1) for erlotinib (n=17) vs 3·7
months (0.3, 49.3) for placebo (n=11).
Secondary outcomes:
1. Progression free survival
Six trials reported PFS (EURTAC; TORCH; CHEN; FASTACT 2; OPTIMAL; ENSURE). One trial did not report hazard ratios
and only presented limited data (TOPICAL) and no data were reported in one trial (GTOWG).
The pooled treatment effect estimate for four trials (HR of 0.30 (95% CI: 0.24, 0.38, fixed effect, I2=74%, 4 trials) favoured
erlotinib (OPTIMAL; EURTAC; TORCH; ENSURE). As there was a substantial amount of heterogeneity, a sensitivity analysis
was performed using the random effect model and results were similar to the main analysis (HR 0.31 (95% CI: 0.20, 0.50).
CHEN reported a HR of 0.55 (95% CI: 0.21, 1.46) for PFS indicating no significant difference between the groups. FASTACT
2 reported a significant difference in PFS favouring erlotinib plus CTX (HR of 0.25 (95% CI: 0.16, 0.39) (Analysis 1.2)
The median progression free survival was reported for TOPICAL which was 4.8 months (1.6, 8.8) for erlotinib (n=17) and 2.9
months (0.3, 10.1) for placebo (n=11).
2. Tumour response
The pooled treatment effect estimate for five trials (OPTIMAL; TORCH; EURTAC; GTOWG; ENSURE) favoured erlotinib (RR
2.26 (95% CI: 1.85, 2.76, I2=57%, 5 trials). As there was a substantial amount of heterogeneity a sensitivity analysis was
performed using a random effect model and results were similar (RR 2.20 (95% CI: 1.53, 3.17), Analysis 1.3).
CHEN reported a RR of 0.83 (95% CI: 0.19, 3.67) for tumour response, indicating no significant differences in tumour
response between the groups in a trial of 24 patients.
FASTACT 2 observed an objective response in 41 (84%) of 49 patients with EGFR-activating mutations in the erlotinib plus
CTX group and seven (15%) of 48 in the chemotherapy plus placebo group (RR 5.74 (95% CI: 2.86, 11.50).
TOPICAL did not report tumour response for EGFR M+ patients.
3. Toxicity and adverse effects of treatment b b
The most commonly reported AEs Table 1 in patients treated with erlotinib as a monotherapy (CHEN;ENSURE; EURTAC;
GTOWG; OPTIMAL; TOPICAL; TORCH) were rash, diarrhoea and fatigue. Other AEs included mouth ulcers, constitutional
symptoms nausea, increased ALT, dyspnoea and pulmonary toxicities. Where erlotinib was administered in combination with
cytotoxic chemotherapy (FASTACT 2), the commonly reported AEs were neutropenia, thrombocytopenia and anorexia.
4. Quality of life
Two trials reported on the QoL of EGFR M+ patients (TORCH; OPTIMAL). One trial used the Lung Cancer Symptom Scale
(LCSS) to measure QoL, but compliance was so poor that the analysis was regarded as inconclusive by the authors (
EURTAC).
QoL was measured but not reported in the trial reports in three trials (GTOWG; HIRSCH) and was not available for the EGFR
M+ subgroup in three trials (FASTACT 2; CHEN; TOPICAL).
TORCH used the the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire -
Core 30 (QLQ-C30) questionnaire and the lung cancer specific module (EORTC QLQ-LC13) to evaluate QoL. The number of
patients improved/ stable/ worse is reported for selected and unselected patients receiving erlotinib and chemotherapy. In the
small numbers of EGFR M+ patients (n=36/39 available for analysis) patients' improvement in terms of global QoL and
physical functioning was particularly evident for erlotinib compared to CTX.
OPTIMAL used the FACT L, Lung cancer symptom score (LCSS) and trial outcome index (TOI) scales to assess QoL. The
odds ratios (with co-variates EGFR mutation type, smoking history and histological type) were in favour of erlotinib and were
6.69 (95% CI: 3.01, 14.85; p=0.0001), 7.54 (95% CI: 3.38, 16.85; p= 0.0001), and 8.07 (95% CI: 3.57, 18.26; p=0.0001).
In the ENSURE trial deterioration in TOI was 11.4 months for erlotinib compared to 4.2 months for chemotherapy (HR 0.51
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95% CI 0.34-0.76 p=0.0006 and time to deterioration in QoL was 8.2 months for erlotinib compared to 2.8 months for
chemotherapy( HR 0.64 95% CI 0.44-0.93 p=0.0168)
5. Symptom palliation -
In the TORCH trial the time to deterioration curves for cough, dyspnoea and pain in the first 20 weeks were visually assessed
for erlotinib vs chemotherapy, and no major differences were observed. No statistical analyses were provided by the authors.
In the OPTIMAL trial, it was reported that the time to improvement of symptoms on Trial outcome index (TOI), LCSS and
EORTC Q-30 was significantly shorter for erlotinib compared to chemotherapy FACT-L 1.51 vs 3.19 months (p=0.0067); TOI
2.79 vs 3.48 months (p=0.003); LCS 1.48 vs 3.15 months (p=0.0010). There was also significant correlation between overall
response and improvement in symptom scores (p=0.0006, 0.0002 and 0.0213 respectively for FACT-L, TOI and LCS).
In the ENSURE trial, preliminary data has shown using the FACT-L questionnaire, that time to symptomatic progression was
13.8 months for erlotinib compared to 5.5 months for chemotherapy (HR 0.56 (0.36-0.87) p=0.0076.
Gefitinib vs CTX
Gefitinib vs gemcitabine plus cisplatin: One trial considered this comparison (First-SIGNAL).
Gefitinib vs paclitaxel plus carboplatin: Two trials considered this comparison (IPASS; NEJSG).
Gefitinib vs docetaxel plus cisplatin: One trial considered this comparison (WJTOG3405).
Data could not be combined for all four trials comparing gefitinib to CTX (First-SIGNAL; IPASS; NEJSG; WJTOG3405) as
two trials only reported adjusted analyses (IPASS; NEJSG). It is not advisable to combine adjusted and unadjusted
estimates.
Gefitinib and carboplatin plus paclitaxel or cisplatin plus gemcitabine vs CTX alone: Two trials considered this comparison (
INTACT 1; INTACT 2). However, EGFR M+ specific data from both trials have been analysed as though they were one trial
and therefore data are only presented narratively.
Gefitinib plus pemetrexed and cisplatin versus pemetrexed plus cisplatin. One trial considered this comparison (Yu 2014)
Primary outcome: Overall survival -
The pooled treatment effect estimate for two trials (IPASS; NEJSG) indicated no significant difference in OS between the
groups (HR 0.95 (95% CI: 0.77, 1.18), I2=0, 2 trials). First-SIGNAL reported a HR of 1.04 (95% CI: 0.50, 2.20) and
WJTOG3405 reported a HR of 1.25, 95% CI 0.88-1.78 for OS indicating no significant difference in OS between the groups (
Analysis 2.1).
INTACT 1 and INTACT 2 reported a combined HR of 1.77 [95% CI: 0.50, 6.23] for OS indicating no significant difference in
OS between the groups.
Secondary outcomes:
1. Progression free survival
The pooled treatment effect estimate for two trials (IPASS; NEJSG) showed a significant difference in PFS between the
groups favouring gefitinib (HR 0.39 (95% CI: 0.32, 0.48), I2=73%, 2 trials). As there was a substantial amount of
heterogeneity, a sensitivity analysis was performed using a random effect model and results were similar (HR 0.39 (95% CI:
0.26, 0.59)). First-SIGNAL reported a HR of 0.54 (95% CI: 0.27, 1.10) for PFS indicating no significant difference in PFS
between the groups and WJTOG3405 reported a significant difference in PFS favouring gefitinib (HR 0.49 (95% CI: 0.34,
0.71), Analysis 2.2). ? no pooling ? adjustedcf unadjusted issue again
INTACT 1 and INTACT 2 reported a HR of 0.55 [95% CI: 0.19, 1.60] for PFS indicating no significant difference in PFS
between the groups in a combined total of 32 patients.
2. Tumour response
The pooled treatment effect estimate for four trials (First-SIGNAL; IPASS; NEJSG; WJTOG3405) favoured gefitinib (RR 1.87
(95% CI: 1.60, 2.19, I2=58%, 4 trials), Analysis 2.3). As there was a substantial amount of heterogeneity a sensitivity analysis
was performed using a random effect model and results were similar (RR 1.92 (95% CI: 1.46, 2.52)).
Response at crossover after progression on first-line treatment 
NEJSG report 28.2% of 52 patients in the NEJSG trial responded to carboplatin/paclitaxel after progressing on gefitinib, and
58.5% of 106 patients responded to gefitinib after failing carboplatin and paclitaxel.
INTACT 1 and INTACT 2 reported that 72% (13/18) of EGFR M+ patients responded to gefitinib plus CTX while 40% of
EGFR M+ patients (2/5) responded to CTX alone.
3. Toxicity and adverse effects of treatment
For gefitinib monotherapy (First-SIGNAL; IPASS; NEJSG; WJTOG3405), the most commonly reported AE Table 1 was rash,
followed by liver toxicity, anorexia and diarrhoea. For patients treated with gefitinib plus cytotoxic chemotherapy, (INTACT 1;
INTACT 2) the commonly reported AEs were thrombocytopenia, rash, diarrheoa and neutropenia.
4. Quality of life
Two trials reported on QoL (IPASS; NEJSG). QoL was measured but not reported in the trial reports in one trial (INTACT 2),
not measured in two trials (WJTOG3405;INTACT 1) and not available for the EGFR M+ subgroup in one trial (First-SIGNAL).
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small c...
11 / 73
IPASS used the FACT-L and TOI symptom improvement by the lung cancer subscale (LCS), and achieved 89.5%
compliance for CTX and 94.8% for the gefitinib patients. The proportion of patients showing improvement in FACT-L total
score, TOI and LCS significantly favoured gefitinib over carboplatin plus paclitaxel (FACT-L total score 70.2% vs 44.5%;
odds ratio (OR) 3.01 (95% CI: 1.79, 5.07), TOI 70.2% vs 38.3% OR 3.96 (95% CI: 2.33, 6.71), LCS 75.6% v 53.9%, OR 2.70
(95% CI: 1.58, 4.62)). The time to deterioration data showed a median of 15.6 months for gefitinib compared to 3.0 months
for CTX for FACT-L, 16.6 months compared to 2.9 months for TOI and 11.3 months compared to 2.9 months for LCS
respectively. In the 131 patients who improved on the gefitinib arm, the median time to improvement in all three scores was
either 8 or 11 days.
NEJSG assessed QoL weekly using the Care Notebook and achieved compliance in 72 patients (63%) on chemotherapy
and 76 patients (69%) on gefitinib. They used three categories of physical, mental and 'life' wellbeing, each of which had
three sub-categories. The number of patients improved/ stable/ worse is also reported and there was no difference between
the treatment arms in mental wellbeing. However, the physical and life scales were all better for gefitinib than CTX. The data
for daily functioning is quoted as HR 0.32 (95% CI: 0.17, 0.59; p.0001).
5. Symptom palliation
In the NEJSG trial, patients who received gefitinib had a significantly longer time to deterioration up to 20 weeks than patients
who received paclitaxel plus carboplatin using both 9.1% and 27.3% levels of deterioration. The data for 27.3% deterioration
for pain and shortness of breath showed HR 0.28 (95% CI: 0.17, 0.46; p=0.0001) in favour of gefitinib.
Afatinib vs CTX
Afatinib vs pemetrexed plus cisplatin: One trial considered this comparison (LUX-Lung 3).
Afatinib vs gemcitabine plus cisplatin: One trial considered this comparison (LUX-Lung 6).
Primary outcome: Overall survival
The pooled treatment effect estimate indicated no significant difference in OS between the groups (HR 1.01 (95% CI: 0.78,
1.31), I2=0, n=2 trials, Analysis 3.1), although data for LUX-Lung 6 are immature.
Secondary outcomes:
1. Progression free survival
The pooled treatment effect estimate showed a significant difference in PFS between the groups favouring afatinib (HR 0.42
(95% CI: 0.34, 0.53), I2=90%, n=2 trials, Analysis 3.2). As there was a substantial amount of heterogeneity, a sensitivity
analysis was performed using a random effect model and results were similar (HR 0.41 (95% CI: 0.20, 0.83).
2. Tumour response
The pooled treatment effect estimate favoured afatinib (RR 2.71 (95% CI: 2.12, 3.46, I2=0%), n=2 trials, Analysis 3.3).
3. Toxicity and adverse effects of treatment
The most commonly reported AEs in the afatinib-treated patients (LUX-Lung 3; LUX-Lung 6) were rash and diarrhoea,
paronychia and stomatitis/mucositis Table 1.
4. Quality of life
LUX-Lung 3, using the QOL C-30 scale, improvement was noted in global health, overall health, physical, cognitive and role
function in favour of afatinib over cisplatin plus pemetrexed chemotherapy.
LUX-Lung 6 also used the QOL C-30 scale and the lung cancer specific module QLQ-LC13 with >90% compliance. In the
LUX-Lung 6 trial the EORTC QLQ-C30 and the lung cancer specific module QLQ-LC13 were used and showed that
compared to cisplatin/gemcitabine a greater percentage of patients showed improvement in global health scores/QoL scores
(p<0.0001, physical (p<0.0001) and social function (p<0.0001) with afatinib. Subgroup analysis showed delay in time to
deterioration in cough, dyspnoea and pain.
5. Symptom palliation
In the LUX-Lung 3 trial time to deterioration curves for cough and dyspnoea showed a significant effect in favour of afatinib
(HR 0.60 (95% CI 0.41, 0.87) p=0.007 and HR 0.68 (95% CI: 0.50, 0.93 p=0.02) respectively. The HR for pain 0.83 (95% CI:
0.62, 1.10) was not statistically significant (p=0.19).
In the LUX-Lung 6 trial time to deterioration for cough (HR 0.45;p=0.0003), dyspnoea (0.54: p<0.0001) and pain (HR
0.70:p=0.003) showed a significant effect in favour of afatinib (HR 0.56, 95% CI 0.41, 0.77, p=0.0002).
Cetuximab plus CTX vs CTX
Cetuximab plus paclitaxel or docetaxel plus carboplatin vs paclitaxel or docetaxel plus carboplatin: One trial considered this
comparison (BMSO99).
Cetuximab plus vinorelbine plus cisplatin vs vinorelbine plus cisplatin: One trial considered this comparison (FLEX).
Primary outcome: Overall survival
Data could not be pooled for the two trials comparing cetuximab plus CTX to CTX as one trial only reported an adjusted
analysis (FLEX).
BMSO99 reported a HR of 1.62 (95% CI: 0.54, 4.84) for OS indicating no significant difference in OS between the groups (
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Analysis 4.1).
FLEX reported a HR of 1.48 (95% CI: 0.77, 2.82) for OS indicating no significant difference in OS between the groups (
Analysis 4.1).
Secondary outcomes:1. Progression free survival
Data could not be pooled for the two trials comparing cetuximab plus CTX to CTX as one trial only reported an adjusted
analysis (FLEX).
BMSO99 reported a HR of 1.17 (95% CI: 0.36, 3.80) for PFS indicating no significant difference in PFS between the groups (
Analysis 4.2).
FLEX reported a HR of 0.92 (95% CI: 0.53, 1.60) for PFS indicating no significant difference in PFS between the groups (
Analysis 4.2).
2. Tumour response
The pooled treatment effect estimate (RR 1.43 (95% CI: 0.83, 2.47, I2=40%), n=2 trials) indicated no significant difference
between the groups (Analysis 4.3).
3. Toxicity and adverse effects of treatment
The most commonly reported AEs Table 1 in the cetuximab-treated patients (BMSO99; FLEX) were neutropenia, leukopenia,
febrile neutropenia and fatigue. It should be noted that cetuximab was administered in addition to cytotoxic chemotherapy
and not as a monotherapy.
4. Quality of life
The cetuximab plus CTX trial (FLEX) used QOL C-30 and the LCSS and found no difference compared to CTX alone across
all entered patients.
QoL was not available for the EGFR M+ subgroup in BMSO99.
5. Symptom palliation
Neither trial reported specifically on symptom palliation.
Toxicity and adverse effects of treatment - general comments
The reporting of adverse events (AEs) differed across the 19 included trials. In Table 1 we describe the trial-defined reporting
of AEs and tabulated the three most frequently occurring Grade 3 or 4 AE for both the intervention and comparator arms of
each trial. The data reported are for overall trial populations and therefore include non-EGFR M patients in trials where
patients were unselected. In Table 1 the trials are grouped according to the EGFR-targeted treatment employed (afatinib,
erlotinib,gefitinib,cetuximab).
Pneumonia is often associated with lung cancer and can be difficult to distinguish from pneumonitis, a recognised adverse
effect of the TKIs. The authors did not consider these reports as reliable, and have quoted a large meta-analysis of data from
separate groups of patients treated with erlotinib and gefitinib in the Discussion. LUX lung 3 and LUX lung 6 reported 3 and 2
patients with interstitial lung disease respectively (1%) in the afatinib arms.
The AEs associated with cytoxic chemotherapy in all comparisons were neutropenia, fatigue, leukopenia, vomiting, anaemia,
decreased appetite, diarrhoea, anorexia, thrombocytopenia, arthralgia, neuropathy and dyspnoea.
Assessment of reporting biases
Sufficient trials were not included in the meta-analyses in order to construct a funnel plot to assess publication bias.
However, we devised and carried out a thorough search strategy to reduce the impact of publication bias.
Subgroup analyses
Sufficient trials were not included to allow subgroup analyses.
Sensitivity analyses
We were unable to include sufficient trials in any one meta-analysis that would allow the sensitivity analyses specified in the
methods section to be undertaken. However, where we detected moderate heterogeneity we used a random effect model as
a sensitivity analysis to compare results with the fixed effect model. These are reported in the effect of interventions section.
Network meta-analysis
We considered that network meta-analysis (NMA) was not appropriate due to the different populations aross the included
trials. We identified other barriers to conducting NMA: two trials reported adjusted analyses (IPASS; NEJSG) whereas all
other trials reported unadjusted analyses; patients in all trials were allowed to switch treatment after progression and we had
no information regarding how this was handled in the analysis for OS. Finally, the Kaplan-Meier plots shown in the trial
reports crossed in four of the trials, indicating that using a Cox proportional hazards model may not be appropriate.
Summary of findings table
Summary of findings ables are presented for pooled analyses for the outcomes of OS and PFS.
Discussion 
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Summary of main results
This review includes 19 RCTs with a combined total of 2317 patients with EGFR M+ NSCLC. We identified four EGFR-
targeted treatments: afatinib (2 trials); erlotinib (8 trials); gefitinib (6 trials); cetuximab (2 trials). We did not consider that NMA
would be appropriate due to the different populations of included trials, the reporting of adjusted analyses vs unadjusted
analyses and the inappropriate use of the Cox proportional hazards model in some trials.
Our primary endpoint was OS for which we found no evidence of any robust OS benefit for any of the EGFR-targeted
treatments when compared with CTX or placebo. The findings of one trial (FASTACT 2) did report a statistically significant
OS gain for patients treated with erlotinib plus CTX when compared to CTX alone; however, this was based on a small
sample of 97 patients. The trial employed an intercalated approach to avoid potential antagonism from concomitant
chemotherapy and TKI. The majority of the included trials of monotherapy allowed patients to switch treatments on disease
progression and this will have a confounding effect on any OS analysis. No OS effect was demonstrated in exploratory
analyses of erlotinib in OPTIMAL or EURTAC or gefitinib IPASS, WJTOG3405 or NEJSG. A recent paper reports a pre-
specified analysis of the Del19 subgroup across a pooled analysis of both of the afatinib trials. The analysis demonstrates an
OS advantage for afatinib compared to chemotherapy, while the L858R subgroup (codon 21 mutation) showed no OS benefit
(Yang 2014). Notably, crossover to afatinib in the control arm was not available, whilst in the majority of comparisons of
erlotinib and efitinib with CTX, crossover to the corresponding TKI was allowed.
For the secondary endpoint of PFS, a pooled analysis of 4 trials of erlotinib (ENSURE; EURTAC; OPTIMAL; TORCH)
demonstrated a statistically significant benefit compared with CTX (HR=0.31; 95% CI: 0.24 to 0.39) in 595 patients. Of the
non-pooled trials, for erlotinib vs CTX, CHEN reported a non-significant effect of erlotinib (n=24) and FASTACT 2 (n=97)
reported a significant PFS benefit for erlotinib (HR=0.25; 95% CI:0.16 to 0.39). In a pooled analysis of gefitinib trials (n= 491)
IPASS and NEJSG demonstrated a significant benefit of gefitinib compared with paclitaxel with carboplatin (HR=0.39; 95%
CI:0.32 to 0.48). A single trial WJTOG3405 also demonstrated a significant difference in PFS favouring gefitinib (HR=0.49;
95% CI: 0.34 to 0.71). One other trial (First-SIGNAL) demonstrated no statistically significant benefit of gefitinib compared
with gemcitabine plus cisplatin (n=42). The remaining 2 trials that featured gefitinib (INTACT 1; INTACT 2) reported no
difference between a regimen of gefitinib plus CTX compared with CTX plus placebo (n=32). Heterogeneity was high in the
pooled analyses of both erlotinib and gefitinib. Five trials ( LUX-Lung 3,EURTAC, OPTIMAL,NEJSG,IPASS) all showed a
significant improvement in PFS for the TKI in tumours harbouring the Del19 mutation compared to chemotherapy. Meta-
analysis of this mutation site -specific data has not been performed.
In a pooled analysis of afatinib (N=709) LUX-Lung 3; LUX-Lung 6 a statistically significant PFS benefit in favour of afatinib
compared with chemotherapy was found (HR=0.42; 95% CI 0.34 to 0.53). It should be noted that the LUX-Lung 3 trial used
cisplatin plus pemetrexed as the comparator, a chemotherapy combination demonstrated to have a superior OS benefit
compared with cisplatin plus gemcitabine in non-squamous NSCLC (Brown 2013). No statistically significant PFS benefit for
cetuximab plus CTX (n=81) was reported in either of the two trials (BMSO99; FLEX). It is not possible to draw any
conclusions as to the advantages of adding CTX to targeted therapy from these data.
In the analysis of tumour response, a pooled analysis of 4 trials of erlotinib including 387 patients (EURTAC; GTOWG;
OPTIMAL; TORCH) favoured treatment with erlotinib (RR=2.57; 95% CI:1.97 to 3.34). One single trial of erlotinib plus CTX
(n=97) also favoured treatment with erlotnib (FASTACT 2) whilst 1 other small trial of erlotinib vs CTX (CHEN) reported no
benefit of erlotinib (n=24, respectively). For gefitinib, all 6 trials demonstrated a statistically significant benefit for gefitinib
compared to CTX; a pooled analysis of 4 trials including 648 patients (First-SIGNAL; IPASS; NEJSG; WJTOG3405) yielded
a RR of 1.87 (95% CI:1.60 to 2.19). Both afatinib trials (n=709) reported a statistically significant benefit of afatinib compared
with CTX (LUX-Lung 3; LUX-Lung 6) and the pooled analysis yielded an RR of 2.71 (95% CI:2.12 to 3.46). As for the PFS
analyses, heterogeneity was high for the erlotinib and gefitinib pooled comparisons and low for the two afatinib trials. No
benefit for cetuximab was reported for either trial (BMSO99; FLEX).
The most commonly reported AEs for patients treated with TKI monotherapy were rash, diarrhoea, paronychia,
stomatitis/mucositis (afatinib), rash, diarrhoea and fatigue (erlotinib and gefitinib). These are consistent with those listed in
the Summary of Product Characteristics for these products which include diarrhoea, rash, interstitial lung disease, liver
impairment and ocular disorders. Patients treated with cytotoxic CTX experienced the AEs usually associated with this
treatment, e.g. neutropenia, febrile neutropenia, leukopenia and fatigue. It is however, difficult to accurately characterise and
compare AEs across trials due the different methods of reporting (definitions used and styles of reporting). This is particularly
relevant to the rare but serious AE of interstitial lung disease. A recent meta analysis (Shi 2014) of erlotinib and gefitinib trials
reported an incidence of 1.2% for interstitial lung disease with a mortality rate of 22.8%. The data presented for afatinib
suggests this rare but serious complication occurs as frequently with all three TKIs, although no data on duration of therapy
was provided. In addition, it should be cautioned that the AEs reported are relevant to an overall trial population and in the 12
trials where EGFR M+ status was not an inclusion criterion, are drawn from a much larger population. However, our
comparisons highlight the differences in the AEs associated with TKIs and cytotoxic CTX (Pilkington 2012).
Quality of life for patients with EGFR M+ tumours was measured by a number of different methods in six trials (2 comparing
afatinib with CTX, 2 comparing erlotinib with CTX and 2 comparing gefitinib with CTX) and a beneficial effect of the TKI
compared to CTX was reported in all six trials. Symptom palliation of cough, pain and dyspnoea was shown for all three TKIs
although there was no standardisation of methodology used.
Any benefit in survival has to be weighed against increased toxicity. The median number of chemotherapy cycles given in the
control arms was four out of a planned six 3-weekly cycles. The oral agents were generally given until progression and
appeared to be better tolerated. The median duration of therapy was estimated to be around 9-12 months. In the 2 gefitinib
trials where data were presented, the number of patients discontinuing therapy was similar to that for CTX, while in the
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EURTAC trial a higher proportion of patients on chemotherapy than erlotinib discontinued on account of toxicity.
Overall completeness and applicability of evidence
The number of events remains small and the analyses remain preliminary in many trials (author calculated median follow-up
of 28 months). We expect mature data in the next 2 years. Median survival of patients with advanced Stages III, IV NSCLC is
of the order of 12 months, and of adenocarcinomas 18 months. At present, there is no indication that increases in PFS fully
translate into OS benefit. This is consistent with the evidence in the current literature base (Booth 2012). However, there is
wide variation in the selection criteria for these different trials, including age, sex, smoking and EGFR sequencing method
based criteria. The later trials recruited patients only with proven EGFR mutations and longer survival times are seen.
However, with the comparatively short survival in NSCLC, AEs and QoL for either first-line or second-line treatments are
important. The interpretation of OS is limited by crossover in most trials. From the limited data available on crossover at
disease progression, the targeted agents and cytotoxics would appear to act on different cell populations.
Mutations in EGFR can be assessed by several methods including direct sequencing of the tumours, circulating tumour cells
(Maheswaran 2008) or cell-free DNA (Bai 2013). Heterogeneity in the proportion of malignant and normal/stromal cells in the
tissues sampled may contribute to variation in the classification of tumours as EGFR M+ or EGFR wild type where a tissue
biopsy is sampled as in the majority of trials in this review (Tsiatis 2010), and there is preliminary evidence of heterogeneity
of mutation analysis with multiple tissue sampling (Bai et al 2013). Secondly, methodological issues in the assessment of
EGFR mutations may contribute to false negative results (Vogelstein 2013). Immunohistochemical-only categorisation of
mutation was excluded from this review.
There are limited data provided on the types of mutations in relation to their sensitivity to targeted therapy (EURTAC). Of the
three common sites of mutation, there is some evidence that tumours with codon 20 mutations are more resistant than exon
19 or L858R codon 21 mutations (Yasuda 2011). A preliminary report of a pooled analysis of patients with an exon 19
deletions or L858R mutations showed improved survival of afatinib compared to CTX (HR 0.81 CI 0.66-0.99 p<0.037) (Yang
2014). Some trials did not include assessment of exons 18 and 20 mutations. Secondly K-RAS and HER-2 mutations may be
associated with resistance to primary treatment (Linardou 2008), but in the cetuximab trials they were assessed and
demonstrated no predictive effect of the biomarkers. Non-randomised trials have shown that some mutations, principally
T90M in codon 20, may contribute to the development of acquired resistance to these agents (Kosaka 2006; Rosell 2011; Su
2012). Only two of the included trials excluded T90M mutations (NEJSG;FLEX).
With improving data on individualisation of treatment according to morphological and molecular criteria, patient choice may
be a factor in the decision to accept significant toxicity (e.g. from CTX) at an earlier or later stage of NSCLC management.
This review provides strong data supporting first-line EGFR TKI in patients where EGFR mutation status is known to be
positive. As mutation testing is not universally available, or the response time of reporting is prolonged, chemotherapy may
be an acceptable first-line option where histological subtype and smoking history are known in patients with good
performance status. Quality control of mutation profiling methodology and international agreement on standardisation would
improve confidence in the use of EGFR TKIs in EGFR M+ patients.
There is some published evidence of ethnic differences in platinum based haematological toxicity, with Asian patients having
a higher incidence of Grade 3/4 neutropenia compared to non-Asian patients based on a pooled analysis of 11,271 patients
in 50 phase II and III trials (Hasegawa 2011). It is less well established if there are ethnic differences in response to targeted
therapies and the trials reported showed wide variation in the ethnic composition of the trials and the majority of the data
comes from Asian patients.
Quality of the evidence
All the included trials were randomised and the overall numbers of patients (n=2317) in the 19 trials provides reasonable
power to support the conclusions. The patients were spread across four different drug treatments (erlotinib, gefitinib, afatinib
and cetuximab), reducing the number providing data for each treatment.
The Risk of Bias table (Figure 2; Figure 3) indicates a mixed risk of bias across the included trials for the majority of the
assessment criteria, most trials are at an unclear or high risk of bias. The two items that were considered to be at high risk of
bias across the trials were related to blinding of treatment allocation for patients and personnel and blinding of outcome
assessment. In trials that compare oral therapy with intravenous chemotherapy treatments, blinding of participants and
administrators is difficult to achieve and even if blinding procedures were implemented, the appearance of a rash (a common
side-effect of treatment with a TKI) would indicate the treatment regime used. FASTACT 2 was blinded in both treatment
allocation and imaging assessment. Blinding of outcome assessment is important when time to treatment failure outcomes,
such as PFS, are the indicators of treatment efficacy and blinded outcome assessment or blinded review of assessment
should be part of the trial protocol . Of the large industry funded trials, for erlotinib OPTIMAL did not report blinding of
outcome assessment, neither did IPASS or WJTOG3405 for gefitinib. We acknowledge that some trials may have
implemented such procedures but did not report on them.
The comparisons with CTX were in general direct, but there was wide variation in the choice of CTX in the comparator arm.
This reflects variation in clinical practice and in particular performance status and co-morbidity of the NSCLC populations.
For example, single agent vinorelbine, used as the comparator in two of the smaller erlotinib trials (CHEN;GTOWG) is
associated with lower toxicity than the more widely used doublet chemotherapy combinations utilised in the other trials, and
patients for both these trials were selected on the basis of age ( >70) and not primarily performance status. The trials also
varied in the extent to which they included never or former smokers, and in the male/female ratio. The other major factor
contributing to heterogeneity is ethnicity, as the 8 trials recruiting exclusively in Asia contributed 64% of the patients. All these
factors may contribute to variation in drug handling of both CTX and targeted therapy. Heterogeneity was high for
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assessment of PFS for erlotinib, gefitinib and afatinib comparisons in the pooled data.
A degree of caution should be taken in the interpretation of the results. Only 7 of the included trials recruited patients solely
based on their EGFR mutation status (n=1672). This means that the data extracted from the remaining 12 trials (n=645) are
derived from subgroups, with all the issues that the interpretation of subgroup data entails. It is worth noting however, that
the subgroup of EGFR M+ patients in the IPASS trial, at 261, was larger than the the total trial population of four of the EGFR
M+ only trials (EURTAC; NEJSG; OPTIMAL; WJTOG3405). It should be further noted that for four trials, the tissue analyses
were carried out retrospectively on a limited number of samples that were available at the end of the trial (BMSO99; FLEX;
INTACT 1; INTACT 2). These four trials however provided data from only 113 patients, and 80 of these were participants in
the cetuximab trials. We do not believe this factor has an impact on the conclusions in respect of the three TKIs.
The confidence limits of the PFS and OS plots are narrow, with the exception of the small trial with erlotinib (CHEN) and
suggest the data are precise. Wider confidence limits are seen for response, which may reflect the subjective nature of the
assessment, even with external review, and current concerns PFS is the better end-point for trial assessment where
crossover is a factor (Booth 2012).
There is evidence that Asian patients have a different proportion of EGFR M+ and differing relationship to smoking which
may imply these are biologically different diseases. Of the 2317 patients reported on in this review, 1591 were recruited
exclusively in trials conducted in Asian countries. We can find no evidence there is a different set of mutations in Asian and
Caucasian patients, or differences in their toxicity profiles for the targeted or chemotherapy arms of the included trials.
Potential biases in the review process
We excluded trials that utilised EGFR-targeted treatments but did not report any EGFR mutation testing of patients.
However, inspection of review papers and reference lists indicated that in relation to four of these trials BMSO99; FLEX;
INTACT 1; INTACT 2, retrospective analyses of tissue samples from patients had taken place, the results of which were
reported in papers separate to the original trial publication. It is possible that there are other retrospective analyses that we
did not identify; however, the patient population from any such analyses is likely to be small.
Agreements and disagreements with other studies or reviews
The results are in agreement with the meta-analysis of Ku 2011 which compared gefitinib with first-line chemotherapy. A
more recent meta-analysis of 14,570 patients given TKIs in first-line, second-line and maintenance RCTs also supported gain
in progression-free survival in EGFR M+ patients treated with erlotinib and gefitinib (Lee 2013). This analysis included data
on subgroups of patients (n= 67) from TALENT, TRIBUTE and TOPICAL which were not available to us at the time of
analysis. No data on patient characteristics, toxicity and quality of life were analysed in the Lee review. Their analysis
combined the data from 10 first-line trials in a meta-analysis of OS and PFS and showed an overall HR of 0.43 CI 0.38-0.49
(p<0.001) for PFS and no effect on OS. As described above, we consider this pooling inappropriate on statistical grounds as
adjusted and unadjusted data were combined. An updated meta-analysis by the same group focused on seven trials (
ENSURE; EURTAC;LUX-Lung 3;LUX-Lung 6;NEJSG;OPTIMAL;WJTOG3405) and concluded that never-smokers, those with
tumours with exon 19 deletions and women had a greater benefit from erlotinib than chemotherapy (Lee 2015). Other
reviews have combined data from 7 Hasegawa 2015 and 8 phase lll trials Haaland 2014 for first line chemotherapy and
confirmed the benefit in PFS and response. The data on benefit in non-smokers is difficult to interpret. Our review of patients
across 19 trials includes additional trials and comparable data from the 2317 EGFR M+ patients on afatinib, erlotinib and
gefitinib. A recent individual patient meta analysis (Pujol 2014) of four RCTs of cetuximab (including BMSO99 and FLEX) in
NSCLC reported improved PFS in squamous cell cancers (based on a subgroup analysis) but not in non-squamous
carcinomas, although these data were not analysed by mutation status ? Add necitumumab .
Authors' conclusions 
Implications for practice 
Erlotinib, gefitinib and afatinib are effective in EGFR M+ NSCLC patients with acceptable toxicity. Quality of life and response
are closely linked, and the available data would favour selection of TKIs over chemotherapy based on both these criteria,
although only 6 trials reported on quality of life solely in the EGFR M+ population. The majority of trials included patients with
a PS of 1 and 2, but the data on AEs suggest some PS 3 as well as elderly patients might tolerate the agents better than
cytotoxic CTX (GTOWG:CHEN). They may also be an alternative to best supportive care in patients unsuitable for
chemotherapy. Other reviews (Brown 2013) have concluded that the CTX standard for non-squamous NSCLC should now
be cisplatin and pemetrexed, at least in patients of good PS. In locations where mutation testing is not available a decision
may have to be made on the basis of histology, gender, smoking history and ethnicity about the selection of first-line TKI
therapy or chemotherapy. In patients with good PS, the intercalated regimen of erlotinib and CTX is another option for this
population in view of its OS benefit in one trial (FASTACT 2). Mature data on OS expected within 2 years should provide
more definitive guidance.
The AEs summarised in this review have underlined the difference between the reduced toxicities experienced with TKI
therapy and those associated with cytotoxic chemotherapy. This will have implications for care of patients and the costs of
healthcare provision (Pilkington 2012).
Implications for research 
Future trials of these agents should comprise patients with known EGFR mutations, and attempt to clarify the effectiveness in
the individual mutant subtypes (codons 19,20 and 21) as well as the small numbers with multiple mutations and rare
mutations. There is increasing evidence that patients with T90M mutations should be excluded from trials with afatinib,
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erlotinib and gefitinib. Irreversible inhibitors of EGFR are under development along with monoclonal antibody therapies in
addition to cetuximab. Biomarker trials may help to select patients in which optimal activity will be demonstrated - for
example codon 19-21 mutations are more likely to be associated with receptor internal domain alterations which will not
respond to the ligand binding action of cetuximab (Khambata-Ford 2010), and as the preliminary data presented here have
shown, individual TKIs may prove more effective for specific codon alterations. One recent trial still in progress has shown a
response rate of 64% in patient with tumours harbouring the T90M mutation (Janne 2014 ). It follows that stratification of
NSCLC patients by an appropriate molecular profile will progressively evolve with the introduction of new agents.
The role of combination of EGFR targeted therapy and cytotoxic chemotherapy and the associated toxicity remains to be
established, but the data from the BMSO99; FLEX; INTACT 1; INTACT 2 trials do not favour this approach, either in terms of
efficacy or toxicity. The FASTACT 2 trial demonstrated positive outcomes from the combination of erlotinib with CTX given in
an intercalated design; however, the number of EGFR M+ patients in these trials was small. Three randomised trials have
addressed the issue of maintenance therapy after a response or stable disease to CTX, two with erlotinib ( Capuzzo 2010:
Perol 2012), the third with gefitinib ( Zhang 2012) see meta analysis review  - can't find this now . These trials
showed an overall PFS gain for maintenance erlotinib or gefitinib respectively, and this effect was significant in the EGFRM+
subgroups in the Capuzzo 2010 and Zhang 2012 trials. There was no significant OS benefit in any of the maintenance trials.
These trials may be worth repeating with patients selected by EGFR M+ status. Crossover designs with alternative targeted
therapies should be initiated by academic groups, as these are unlikely to attract industry funding . Evidence is accumulating
of different subgroups of non-squamous NSCLC based on driver gene mutations such as the ALK gene rearrangement, and
these would appear to be mutually exclusive with the EGFR M+.
Further comparative trials with cytotoxic chemotherapy would seem unlikely to be of value, and the focus should be on
identifying the predictive value of specific mutations to optimise survival and minimise toxicity. Future trials should report in
detail on the degree and duration of symptom control as well as quality of life scores.
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Published notes 
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Characteristics of included studies 
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Methods Open-label, randomised, phase III, multicentre trial conducted in the USA.
Length of follow-up: not reported
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=17) is retrospective and reported in a paper separate to the primary published
paper.
 
Participants 676 patients with histologically or cytologically confirmed Stage IV, Stage IIIB (with
malignant pleural effusion), or recurrent (after radiotherapy or surgery) NSCLC with
bidimensionally measurable disease;
Inclusion criteria: >18 years; ECOG PS < 2. Patients with previously treated CNS
metastases accepted, but patients with symptomatic, uncontrolled disease or requiring
corticosteroids were not. Prior surgery (4 weeks) or chest radiation (12 weeks) but no
prior chemotherapy for NSCLC or EGFR-targeted therapy.
Exclusion criteria: previous infusion reactions to chimerized/murine MABs;
pregnant/nursing women;history of acute myocardial infarction (3 months prior); Grade
2 peripheral neuropathy; inadequate hematologic, hepatic, or renal function.
Median age: 64 years
Male:57%
Ethnicity: 88% White
 
Interventions Treatment arm (8/338 patients EGFR M+): cetuximab plus taxane/carboplatin
Comparator arm (9/338 patients EGFR M+): taxane/carboplatin
Cetuximab, the first dose was 400 mg/m2, 120-minute IV, with subsequent doses of
250 mg/m2, 60-minute IV, weekly until disease progression or intolerable toxicity, even
after completion of chemotherapy.
Paclitaxel 225 mg/m2, 3-hour IV, or docetaxel 75mg/m2, 1-hour IV) with carboplatin
(area under the curve = 6, 30-minute IV) on day 1 every 3 weeks until disease
progression or intolerable toxicity for six cycles.
 
Outcomes Primary outcome: PFS (based on modified WHO criteria)
Secondary outcomes: ORR, OS, QoL, safety
 
Mutation Assessment Method QiAamp
 
Exons assessed 18-21
 
Notes The trial was originally designed as a randomised phase II trial to provide non-
comparative data on the efficacy of cetuximab combined with standard chemotherapy
(ORR as primary end point). Ten months after accrual initiation, the protocol was
amended to be conducted as a phase III trial to evaluate the addition of cetuximab to
taxane plus carboplatin, with a primary end point of PFS. Patient accrual was
increased from 300 to 660 patients.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk No information provided on randomisation.
 
Allocation concealment (selection
bias)
Unclear risk No information provided.
 
Blinding of participants and
personnel (performance bias)
High risk This was an open-label trial.
 
Blinding of outcome assessment
(detection bias)
Low risk Independent radiological assessment was undertaken.
 
Incomplete outcome data (attrition
bias)
Low risk 13 patients in cetuximab arm did not receive treatment; 18 patients in the
taxane only arm did not receive treatment. Reasons not given. However,
ITT analysis was carried out.
 
Selective reporting (reporting bias) Low risk All stated outcomes reported.
 
Other bias Unclear risk Trial support from drug manufacturers.
 
CHEN
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Methods Open-label, randomised, phase II trial conducted in Taiwan.
Length of follow up: not reported
The trial included a mixed patient population. The analysis of EGFR M+ data only (n=
24) is presented as subgroup analysis in the primary published paper
 
Participants 113 participants aged 70 years or older with histologic or cytologic diagnosis of
inoperable NSCLC who had never received chemotherapy, targeted therapy, or
hormonal therapy were entered into the trial after giving informed consent.
Inclusion Criteria: ECOG PS of 0–3; measurable lesion(s); no previous radiotherapy on
measurable lesion(s); adequate bone marrow reserve with a granulocyte count more
than or equal to 1500/mm3, platelets more than or equal to 100,000/ mm3, and
haemoglobin more than or equal to 10 g/dL.
Exclusion Criteria: Previous therapy, symptomatic or unstable brain metastases,
inadequate liver or renal function, or uncontrolled systemic disease.
Median age: 77 years
Male:81%
Ethnicity: 100% E.Asian
 
Interventions Treatment arm (9/57 patients EGFR M+): erlotinib 150 mg/daily
Comparator arm (15/56 patients EGFR M+): vinorelbine 60 mg/m2 days 1 and 8 of
every 3-weekly cycle
Responding patients and those with stable disease continued treatment until disease
progression or completion of six cycles. Patients could continue treatment beyond six
cycles provided their disease was controlled
 
Outcomes Primary Outcome:
ORR
Secondary Outcomes:
OS, PFS (RECIST version 1 criteria), Disease control rate, Tolerability, QOL (FACT-L))
 
Mutation Assessment Method VarientSEQr
 
Exons assessed 18-21
 
Notes All participants were aged 70 years or older.
Vinorelbine dose increased to 80 mg/m2¬beginning from cycle 2 if no toxicity of Grade
2 or higher.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Paper states that patients were randomised with stratification. No other
information given
 
Allocation concealment (selection
bias)
Unclear risk Insufficient information given.
 
Blinding of participants and
personnel (performance bias)
High risk The trial was open-label.
 
Blinding of outcome assessment
(detection bias)
High risk No evidence of independent assessment of PFS.
 
Incomplete outcome data (attrition
bias)
Low risk All patients were accounted for.
 
Selective reporting (reporting bias) Unclear risk The protocol states that Time to Progression is a primary outcome. This
is not mentioned or reported in the published paper.
 
Other bias Unclear risk Trial partially sponsored by pharmaceutical company.
 
ENSURE
Methods Open-label, Phase III RCT conducted in Asia
Length of follow up: 28.9 (erlotinib), 27.1 (CTX)
 
Participants 217 patients with stage IIIB/IV non-small cell lung cancer with EGFR mutations in their
tumours
 
Interventions Erlotinib (n=110) 150 mg once daily until progression/unacceptable toxicity
Gemcitabine plus cisplatin (n=117) gemcitabine 1250 mg/m2 i.v. days 1 and 8 plus
cisplatin 75 mg/m2 i.v. day 1, every 3 weeks, for up to four cycles).
 
Outcomes Primary
PFS (RECIST)
Secondary
ORR, DCR, OS, AEs, QoL
 
Mutation Assessment Method Cobas EGFR mutation test (Roche Molecular Systems)
 
Exons assessed 19, 21
 
Notes Estimated Primary Completion Date: December 2015. ClinicalTrials.gov
Identifier:NCT01342965
Trial ended early after interim analysis (73% of PFS events). PFS data cut-off July
2012 and OS data cut-off April 2014
 
Risk of bias table
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Bias Authors' judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk No description given
 
Allocation concealment (selection
bias)
Unclear risk No description given
 
Blinding of participants and
personnel (performance bias)
High risk The trial was open label
 
Blinding of outcome assessment
(detection bias)
Low risk Independent radiological assessment used as a sensitivity analysis
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for in the analyses
 
Selective reporting (reporting bias) Low risk All outcomes measured were reported
 
Other bias Unclear risk Trial stopped after interim analysis
Trial sponsored by pharmaceutical company
 
EURTAC
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Methods Open-label, randomised, phase III trial conducted in Spain, France and Italy
Length of follow-up (months): 41 (erlotinib) and 35 (CTX)
 
Participants 173 patients with NSCLC and EGFR mutations.
Inclusion Criteria:Histological diagnosis of Stage IIIB (with pleural effusion) or Stage IV
NSCLC (based on the sixth TNM staging system), measurable or evaluable disease.
Activating EGFR mutations (exon 19 deletion or L858R mutation in exon 21), age older
than 18 years, and no history of chemotherapy for metastatic disease (neo adjuvant or
adjuvant chemotherapy was allowed if it ended ≥6 months before entry to trial)
Exclusion Criteria:Non-EGFR mutated patients, previous chemotherapy for metastatic
disease
Median age: 65 years
Male:28%
Ethnicity: 92% White
 
Interventions Treatment arm (86/86 patients EGFR M+): erlotinib 150 mg/daily until disease
progression, toxicity or withdrawal of consent
Comparator arm (87/87 patients EGFR M+): cisplatin 75 mg/m² on day 1, docetaxel 75
mg/m² on day 1 or gemcitabine 1250 mg/m² on day 1 and 8. Cycle of 3 weeks for up to
4 cycles
Patients who were ineligible for cisplatin treatment received intra venous carboplatin
chemotherapy instead (3 week cycles of AUC 6 on day 1 with 75 mg/m² docetaxel on
day 1, or AUC 5 on day 1 with 1000 mg/m² gemcitabine on days 1 and 8).
 
Outcomes Primary Outcome:
PFS (RECIST version 1 criteria)
Secondary Outcomes:
OS, ORR
 
Mutation Assessment Method ABI Prism 3130 DNA Analyzer
 
Exons assessed 19, 21
 
Notes EGFR mutation analysis defined as inclusion criteria, therefore all enrolled patients
were EGFR positive. Trial enrolment was stopped at interim data analysis as trial had
met primary endpoint
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Computer-generated randomisation, stratified by EGFR mutation type
and ECOG performance status.
 
Allocation concealment (selection
bias)
Low risk Centralised allocation system used.
 
Blinding of participants and
personnel (performance bias)
High risk The trial was open-label.
 
Blinding of outcome assessment
(detection bias)
Low risk PFS and treatment responses were confirmed by an external review of
CT scans by a central review board.
 
Incomplete outcome data (attrition
bias)
Low risk All patients were accounted for.
 
Selective reporting (reporting bias) Low risk All outcomes reported (trial protocol available via NICE STA process)
 
Other bias Unclear risk Trial sponsored in part by pharmaceutical company.Trial enrolment was
stopped at interim data analysis as trial had met primary endpoint
 
FASTACT 2
Methods Double-blind, placebo controlled, randomised Phase III trial conducted in Asia.
Length of follow-up (months): E=28; CTX=28
The trial included a mixed patient population. The analysis of EGFR M+ data only (n=
97) is presented as subgroup analysis in the primary published paper.
 
Participants 451 patients with stage IIIB/IV NSCLC.
Inclusion criteria: ECOG PS 0 or 1; measurable disease according RECIST version 3.0
Exclusion criteria: previous treatment with agents targeting the HER axis; previous
systemic antitumour treatment;adjuvant or neoadjuvant treatment for non-metastatic
disease within 6 months;surgery less than 4 weeks before the trial; and localised
radiotherapy; brain metastasis; any unstable illness; patients known to be HIV positive
Median age: 58 years
Male:60%
Ethnicity: 100% SE Asian
 
Interventions Treatment arm (49/226 patients EGFR M+): erlotinib 150mg per day plus gemcitabine
(1250 mg/m² on days 1 and 8 of a 4 week cycle, intravenously) plus platinum
(carboplatin 5 × AUC or cisplatin 75 mg/m² on day 1 of a 4 week cycle)
Comparator arm (48/225 patients EGFR M+): placebo plus gemcitabine (1250 mg/m²
on days 1 and 8 of a 4 week cycle, intravenously) plus platinum (carboplatin 5 × AUC
or cisplatin 75 mg/m² on day 1 of a 4 week cycle) plus placebo
 
Outcomes Primary outcome: PFS
Secondary outcomes: OS, ORR, duration of response, TTP, safety
 
Mutation Assessment Method Cobas 4800 system
 
Exons assessed 19, G719X, L858R, or L861Q
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Patients were randomly assigned in a 1:1 ratio by use of a central
randomisation programme with a minimisation algorithm
 
Allocation concealment (selection
bias)
Low risk Central randomisation and drug-pack allocation were assigned by use of
an interactive internet response system.
 
Blinding of participants and
personnel (performance bias)
Low risk Everyone outside the company responsible for the interactive internet
response system was masked to treatment allocation with the exception
of a small independent group that was responsible for monitoring data
and safety early in the trial.
 
Blinding of outcome assessment
(detection bias)
Low risk An independent review committee masked to treatment assignment
reviewed all tumour images and determined tumour response and
progression status.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for in final analysis. ITT analysis conducted. Equal
numbers (n=4) in each arm did not receive allocated treatment.
 
Selective reporting (reporting bias) Low risk All outcomes reported in protocol were assessed an presented in
published paper
 
Other bias Unclear risk Trial sponsored in part by pharmaceutical company.
 
First-SIGNAL
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Methods Open-label, randomised, multi-centre phase III trial conducted in Korea.
Length of follow-up (months) =35
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=42) is presented as subgroup analysis in the primary published paper.
 
Participants 313 Korean never-smokers patients with Stage IIIB or IV lung adenocarcinoma.
Inclusion Criteria: chemotherapy-naive never-smokers older than age 18 years with
Stage IIIB (ineligible for curative radiotherapy) or IV adenocarcinoma of the lung with
measurable or nonmeasurable disease, PS of 0 to 2, and adequate bone marrow, liver,
and renal function.
Exclusion criteria: severe hypersensitivity to gefitinib or any constituents of this
product; any evidence of clinically active interstitial lung disease; severe or
uncontrolled systemic disease; concomitant use of phenytoin, carbamazepine,
rifampin, barbiturate, or St John’s wort; and non-stable brain metastasis
Median age: 57 years
Male:11%
Ethnicity: 100% E Asian
 
Interventions Treatment arm (26/159 patients): gefitinib 250 mg/daily until disease progression
Comparator arm (16/154 patients): cisplatin 75 mg/m2 on day 1 and gemcitabine
1,250mg/m2 on days 1 and 8. Cycle of 3 weeks for up to 9 cycles.
 
Outcomes Primary Outcome:
OS
Secondary Outcomes:
PFS (WHO criteria), QoL (European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire C30 and the lung cancer–specific module LC13),
ORR
 
Mutation Assessment Method QiAamp
 
Exons assessed 19 to 21
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Patients were recruited to the trial by 1:1 random assignment and
stratified by sex, PS and disease stage. No details of randomisation
procedures reported.
 
Allocation concealment (selection
bias)
Unclear risk Insufficient information given.
 
Blinding of participants and
personnel (performance bias)
High risk The trial is open-label.
 
Blinding of outcome assessment
(detection bias)
Low risk Independent blinded assessment of PFS is reported
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for (4 withdrew consent in gemcitabine arm prior
to treatment).
 
Selective reporting (reporting bias) Low risk No protocol available but all outcomes stated as measured in paper are
reported.
 
Other bias Unclear risk Trial sponsored in part by a pharmaceutical company.
 
FLEX
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Methods Open-label, randomised phase III trial conducted internationally.
Length of follow-up (months): Cetuximab = 24; CTX = 24
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=64) is retrospective and reported in a paper published separately from the main
analyses.
 
Participants 1125 chemotherapy-naive patients with histologically or cytologically proven Stage IIIB
or IV NSCLC and IHC evidence of EGFR expression in at least one positively stained
tumour cell.
Inclusion criteria: >18 years, ECOG PS 0-2, adequate organ function, at least one
bidemensionally measurable tumour lesion.
Exclusion criteria: brain metastases, previous treatment with EGFR-targeted drugs or
MABs, major surgery within previous 4 weeks, chest irradiation 12 weeks prior to trial
entry, active infection, pregnancy, symptomatic peripheral neuropathy
Median age: 59 years
Male:70%
Ethnicity: 85% White
 
Interventions Treatment arm (28/557 patients EGFR M+): cetuximab plus cisplatin and vinorelbine.
Cetuximab starting dose of 400 mg/m² intravenous infusion over 2 hrs on day 1, and
from day 8 onwards at 250 mg/m² over 1 hr per week. Cisplatin 80 mg/m² intravenous
infusion on day 1, and vinorelbine 25 mg/m² intravenous infusion on days 1 and 8 of
every 3-week cycle for up to 6 cycles.
Comparator arm (36/568 patients EGFR M+): cisplatin plus vinorelbine.
Cetuximab was continued after the end of chemotherapy until disease progression or
unacceptable toxicity occurred
 
Outcomes Primary outcome:
OS
Secondary outcomes:
PFS (modified WHO criteria), TTP, ORR, QoL, AEs
 
Mutation Assessment Method DxS EGFR29 Mutation Test Kit
 
Exons assessed 19
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Computer generated randomisation schedule.
 
Allocation concealment (selection
bias)
Low risk Centralised IVRS used.
 
Blinding of participants and
personnel (performance bias)
High risk Open-label.
 
Blinding of outcome assessment
(detection bias)
High risk Open-label. No evidence of independent assessment of radiological
outcomes
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for. ITT analysis.
 
Selective reporting (reporting bias) Unclear risk All outcomes reported except disease control rate.
 
Other bias Unclear risk Trial supported by pharmaceutical company.
 
GTOWG
Methods A randomised phase II trial conducted in Germany.
Length of follow-up (months): not reported
The trial included a mixed patient population. The analysis of data for patients with
EGFR M+ tumours (n=10) is retrospective in the primary publication.
 
Participants 284 patients aged 70 years or older with Stage IIIB or IV NSCLC.
 
Interventions Treatment arm (144 patients): erlotinib 150mg/daily
Comparator arm (140 patients): carboplatin AUC 5 d1 and vinorelbine 25mg/m2 day 1,
8 every 21 days for up to 6 cycles
 
Outcomes Primary outcome:
PFS (RECIST criteria)
Secondary outcomes:
OS, response, tolerability, quality of life
 
Mutation Assessment Method Direct
 
Exons assessed Not reported
 
Notes The patient population was over 70 years old.
Only exons 17 and 19 were screened using the ABI 3500 Genetic analyser. Quality of
life is not reported, nor is OS or PFS for EGFR M+ pts. Trial Information taken from
poster provided by trial authors.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Randomised. No information provided. Trial information taken from
conference abstract
 
Allocation concealment (selection
bias)
Unclear risk No information. Trial information taken from conference abstract
 
Blinding of participants and
personnel (performance bias)
Unclear risk No information. No information provided. Trial information taken from
conference abstract
 
Blinding of outcome assessment
(detection bias)
Unclear risk No information
 
Incomplete outcome data (attrition
bias)
Unclear risk Nine patients did not receive treatment but reasons not reported.
 
Selective reporting (reporting bias) High risk Quality of life not reported
 
Other bias Unclear risk Pharmaceutical company support not clear
 
INTACT 1
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Methods Double-blind, randomised, placebo-controlled, phase III trial conducted internationally.
Length of follow-up (months): 15.9
Combined retrospective molecular analysis of INTACT 1 and 2 patients (combined
total of 32) is reported in a publication separate to the main trial publication.
 
Participants 1093 patients histologically/cytologically confirmed NSCLC, locally advanced Stage III
disease not curable with surgery or radiotherapy or Stage IV disease
Inclusion criteria: aged 18 years or older and WHO PS of 0 to 2.
Exclusion criteria (main):previous chemotherapy (prior surgery or localized radiation
were allowed); hypersensitivity to mannitol, corticosteroids, H2-antagonists,
antihistamines or agents formulated with polyoxyethylated castor oil; radiotherapy
within the last 2 weeks; unresolved toxicity from previous radiation therapy or
incomplete healing from previous surgery; pre-existing motor or sensory neurotoxicity,
severe or uncontrolled systemic disease; recent conditions requiring medication or
uncontrolled significant active infections; pregnant or breast-feeding; coexisting
malignancies or malignancies diagnosed within the last 5 years with the exception of
basal-cell carcinoma or cervical cancer in situ; mixed NSCLC plus small-cell lung
cancer
Median age: 60 years
Male:74%
Ethnicity: 90% White
 
Interventions Treatment arm A (365 patients): gefitinib 500mg/daily plus gemcitabine 1,250 mg/m2
IV 30 minutes on days 1 and 8 and cisplatin 80 mg/m2 after gemcitabine administration
on day 1 only.
Treatment arm B (365 patients): gefitinib 250mg/daily plus gemcitabine and cisplatin
Comparator arm (363 patients): Placebo plus gemcitabine and cisplatin
Chemotherapy was administered in 3-week cycles for a total of six cycles:
Subsequently, patients continued
on gefitinib or placebo until disease progression.
 
Outcomes Primary outcome: OS
Secondary outcomes: TTP (RECIST) , response rate and safety
 
Mutation Assessment Method Big dye terminator
 
Exons assessed 18 to 21
 
Notes Number of EGFR M+ patients unclear
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Randomly assigned. No information given.
 
Allocation concealment (selection
bias)
Unclear risk Insufficient information given.
 
Blinding of participants and
personnel (performance bias)
Low risk Double blind placebo controlled design.
 
Blinding of outcome assessment
(detection bias)
Low risk No independent review but outcome assessors were blind.
 
Incomplete outcome data (attrition
bias)
Unclear risk No information.
 
Selective reporting (reporting bias) Low risk No protocol available but all outcomes stated as measured in paper
are reported.
 
Other bias Unclear risk Supported by a grant from AstraZeneca, Wilmington, DE.
 
INTACT 2
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Methods Double-blind, randomised, placebo-controlled, phase III trial conducted mainly in the
USA.
Length of follow-up (months): not reported
Combined retrospective molecular analysis of INTACT 1 and 2 patients (combined
total of 32) is reported in a publication separate to the main trial publication.
 
Participants 1037 patients with histologically confirmed NSCLC, unresectable Stage III or IV
disease
Inclusion criteria: no prior chemotherapy, aged 18 years or older, and WHO PS 0 to 2
Exclusion criteria (main): mixed NSCLC or small-cell lung cancer, brain metastases
that were newly diagnosed or had not been treated with surgery or radiation, previously
treated CNS metastases or spinal-cord compression in the absence of clinically stable
disease, less than 2 weeks since radiotherapy, unresolved toxicity from prior
radiotherapy or incomplete healing from surgery, severe systemic disease, pregnancy
or breast-feeding, and hypersensitivity to mannitol, corticosteroids, H2-antagonists,
antihistamines, or agents formulated with polyoxyethylated castor oil
Median age: 62 years
Male:59%
Ethnicity: 90% White
 
Interventions Treatment arm A (347 patients): gefitinib 500mg/daily plus intravenous paclitaxel 225
mg/m2 over 3 hours on day 1 of a 3-week cycle immediately followed by intravenous
carboplatin area under concentration/time curve of 6 mg/min/mL over 15 to 30 minutes
on day 1.
Treatment arm B (345 patients): gefitinib 250mg/daily plus intravenous paclitaxel 225
mg/m2 over 3 hours on day 1 of a 3-week cycle immediately followed by intravenous
carboplatin area under concentration/time curve of 6 mg/min/mL over 15 to 30 minutes
on day 1
Comparator arm (345 patients): Placebo plus intravenous paclitaxel 225 mg/m2 over 3
hours on day 1 of a 3-week cycle immediately followed by intravenous carboplatin area
under concentration/time curve of 6 mg/min/mL over 15 to 30 minutes on day 1
Chemotherapy was continued for six cycles in the absence of disease progression.
Thereafter, patients were maintained on gefitinib or placebo (control arm) until disease
progression or drug intolerance.
 
Outcomes Primary outcome
OS
Secondary Outcomes
TTP (RECIST criteria), ORR, symptom control, QoL, AEs
 
Mutation Assessment Method Big dye terminator
 
Exons assessed 18 to 21
 
Notes Number of EGFR M+ patients unclear
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Randomised
 
Allocation concealment (selection
bias)
Unclear risk Insufficient information given.
 
Blinding of participants and
personnel (performance bias)
Low risk Double blind placebo controlled design.
 
Blinding of outcome assessment
(detection bias)
Low risk No independent review. But outcome assessors were blinded
 
Incomplete outcome data (attrition
bias)
Unclear risk No information.
 
Selective reporting (reporting bias) Low risk No protocol available but all outcomes stated as measured in paper
are reported.
 
Other bias Unclear risk Supported by a grant from AstraZeneca, Wilmington, DE.
 
IPASS
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Methods Open-label, randomised, phase III trial conducted in East Asia.
Length of follow-up (months): 1
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=261) is retrospective and reported in a paper published separately from the main
analyses.
 
Participants 1217 patients who had advanced pulmonary adenocarcinoma and who were
nonsmokers or former light smokers
Inclusion Criteria: 18 years of age or older, histologically or cytologically confirmed
Stage IIIB or IV NSCLC with histologic features of adenocarcinoma (including
bronchoalveolar carcinoma), were nonsmokers (patients who had smoked <100
cigarettes in their lifetime) or former light smokers (those who had stopped smoking at
least 15 years previously and had a total of ≤10 pack-years of smoking), and had had
no previous chemotherapy or biologic or immunologic therapy.
Median age: 57 years
Male:20%
Ethnicity: 99% E Asian
 
Interventions Treatment arm (132/609 patients EGFR M+): gefitinib 250 mg/daily
Comparator arm (129/608 patients EGFR M+):carboplatin at a dose calculated to
produce an area under the concentration–time curve of 5.0 or 6.0 mg per milliliter per
minute, administered intravenously over a period of 15 to 60 minutes) in cycles of once
every 3 weeks for up to 6 cycles and paclitaxel (200 mg/m2), administered
intravenously over a 3-hour period on the first day of the cycle in cycles of once every
3 weeks for up to 6 cycles
 
Outcomes Primary Outcome:
PFS, (RECIST criteria)
Secondary Outcomes:
OS, ORR, QoL (FACT–L questionnaire, Trial Outcome Index and Reduction in
symptoms, assessed with LCS score), Safety, and adverse-event profile
 
Mutation Assessment Method DxS EGFR29 mutation test kit
 
Exons assessed 18 to 21
 
Notes  
Risk of bias table
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small c...
35 / 73
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Use of dynamic balancing randomisation procedure. Assume computer
program used.
 
Allocation concealment (selection
bias)
Low risk Although not reported in paper, interactive voice response system
system was used (source Astra Zeneca evidence submission to NICE).
 
Blinding of participants and
personnel (performance bias)
High risk Open-label.
 
Blinding of outcome assessment
(detection bias)
High risk PFS was assessed according to RECIST criteria. However, no
independent verification of assessments was reported.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for.
 
Selective reporting (reporting bias) Low risk No selective reporting occurred.
 
Other bias Unclear risk Trial sponsored by pharmaceutical company.
 
LUX-Lung 3
Methods Open-label, phase III, international trial
Length of follow-up (months): 16.4
 
Participants 345 patients with adenocarcinoma, Stage IIIB or IV, EGFR M+ and ECOG PS of 0 to 1
Inclusion criteria: activating mutation in EGFR treatment-naive advanced lung
adenocarcinoma; good performance status (ECOG 0 or 1)
adequate end-organ function; and measurable disease using RECIST version 1.1.
Median age: 61 years
Male:34.5%
Ethnicity: 71% E Asian
 
Interventions Treatment arm (345/345 patients EGFR M+): afatinib 40mg/day, escalated to 50mg if
limited adverse events observed in cycle 1 until progression
Comparator arm (115/115 patients EGFR M+): cisplatin 75mg/m2 and pemetrexed
every 21 days for up to 6 cycles
 
Outcomes Primary Outcome:
PFS
Secondary Outcome:
OS, ORR, Disease Control Rate, tumour shrinkage, QoL ( EORTC QLQ C30 and LC
13), AEs
 
Mutation Assessment Method Therascreen EGFR29
 
Exons assessed 18 to 21
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk BI’s standard validated random number generating system was used to
generate the randomisation schedules, verified by a trial-independent
statistician.
 
Allocation concealment (selection
bias)
Low risk Randomisation was performed centrally using IVRS/IWRS.
 
Blinding of participants and
personnel (performance bias)
High risk Open-label trial.
 
Blinding of outcome assessment
(detection bias)
Low risk Open-label trial but with independent review.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for.
 
Selective reporting (reporting bias) Unclear risk Protocol not available. Outcomes measured unclear from slides.
 
Other bias Unclear risk Trial sponsored in part by pharmaceutical company.
 
LUX-Lung 6
Methods Open label Phase III randomised trial
Length of follow-up (months): 16.6
 
Participants 364 Asian patients all with Therascreen positive EGFR M+ NSCLC
Inclusion criteria: pathologically confirmed and previously untreated stage IIIB or IV
lung adenocarcinoma ECOG PS 0 or 1; measurable disease according to RECIST
version 1.1; adequate organ function. Tumour tissue had to be
EGFR mutation-positive at the screening stage.
Median age: 58 years
Male:34.%
Ethnicity: 90% Chinese
 
Interventions Treatment arm (242/242 patients EGFR M+) afatinib 40mg/day
Comparator arm (122/122 pateints EGFR M+) gemcitabine 1000mg/m2 d 1 and 8 and
cisplatin 75mg/m2 for up to 6 cycles
 
Outcomes Primary outcome:
PFS by central independent review
Secondary outcomes:
Overall response rate, disease control rate, OS, safety, QoL
 
Mutation Assessment Method Therascreen EGFR29
 
Exons assessed 19 to 21
 
Notes HR 0.26 p<0.0001in favour of afatinib . Patient reported outcomes pain , cough and
dyspnea all significantly improved
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Randomisation was done centrally with a random number-generating
system and an interactive internet and voice-response system
 
Allocation concealment (selection
bias)
Low risk As above
 
Blinding of participants and
personnel (performance bias)
High risk Open-label trial.Clinicians and patients were not masked to treatment
assignment,
 
Blinding of outcome assessment
(detection bias)
Low risk The trial investigators who did assessments of patient-reported outcomes
and safety, along with supportive assessments of tumour response (used
for sensitivity analyses), were not masked to treatment assignment.but the
independent central imaging review group were.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for. ITT analysis conducted
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Unclear risk Trial sponsored in part by pharmaceutical company.
 
NEJSG
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Methods Open-label, randomised, phase III trial conducted in Asia
Length of follow-up (months): 24
 
Participants 230 patients with metastatic, non–small cell lung cancer and EGFR mutations
Inclusion Criteria: NSCLC with EGFR mutations, chemo-naive patients aged <75 years
Exclusion Criteria: Previous chemotherapy/targeted therapy, presence of resistant
EGFR mutation T790M
Mean age: 62 years
Male:36.%
Ethnicity: 100% Chinese
 
Interventions Treatment arm (114/114 patients EGFR M+): gefitinib 250 mg/daily until disease
progression, toxicity or withdrawal of consent.
Comparator arm (114/114 patients EGFR M+): carboplatin, dose equivalent to an area
under the concentration–time curve[AUC] of 6, given intravenously over a 1-hour
period on day one every 3 weeks and paclitaxel 200 mg per m2, given intravenously
over a 3-hour period every 3 weeks. Treatment was given for at least 3 cycles until
unacceptable toxicity or withdrawal of consent.
 
Outcomes Primary Outcome:
PFS (RECIST Version 1 criteria)
Secondary Outcomes:
OS,
ORR,
Time to the deterioration of performance status,
AEs
 
Mutation Assessment Method PNA-LNA
 
Exons assessed 19 to 21 (Excluding T90M)
 
Notes EGFR mutation analysis defined as inclusion criteria, therefore all enrolled patients
were EGFR positive
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Block randomisation with block size of 2. Stratification factors of mutation
type, histology and smoking status (source: company submission to
NICE erlotinib 1st line). Assume computer program used.
 
Allocation concealment (selection
bias)
Low risk Centralised allocation.
 
Blinding of participants and
personnel (performance bias)
High risk The trial was open-label.
 
Blinding of outcome assessment
(detection bias)
Low risk Independent radiological review conducted
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for
 
Selective reporting (reporting bias) Low risk All outcomes were reported.
 
Other bias Low risk None identified
 
OPTIMAL
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Methods Open-label, randomised, phase III multicentre trial conducted in China
Length of follow-up (months): not reported
 
Participants 165 patients with NSCLC
Inclusion Criteria: Confirmed EGFR mutations in exon 19 or exon 21 more than 18
years of age and histologically confirmed advanced or recurrent Stage IIIB or IV
NSCLC measurable disease ECOG PS 0–2, adequate haematological, biochemical,
and organ function
Exclusion Criteria: Uncontrolled brain metastases or had received previous systemic
anticancer therapy for advanced disease
Median age: 58 years
Male:40.5.%
Ethnicity: 100% Chinese
 
Interventions Treatment arm (83/83 patients EGFR M+): erlotinib 150 mg/daily until disease
progression
Comparator arm (82/82 patients EGFR M+): carboplatin (area under the curve=5) on
day 1 of a 3 weeks cycle and gemcitabine 1000 mg/m² on days 1 and 8 for up to 4
cycles.
 
Outcomes Primary Outcome:
PFS (RECIST version 1 criteria)
Secondary Outcomes:
OS
ORR
TTP
Duration of response
Safety
QoL, (FACT-L questionnaire and the Lung Cancer Subscale)
 
Mutation Assessment Method Direct
 
Exons assessed 19 to 21
 
Notes EGFR mutation analysis defined as inclusion criteria, therefore all enrolled patients
were EGFR M+
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Patients were assigned (1:1) to either erlotinib or chemotherapy by
dynamic minimisation procedure with Mini Randomisation software.
Central randomisation was done by a clinical research organisation.
 
Allocation concealment (selection
bias)
Low risk Centralised allocation by e-mail and telephone
 
Blinding of participants and
personnel (performance bias)
High risk Open-label
 
Blinding of outcome assessment
(detection bias)
High risk No independent review of radiological outcomes
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Unclear risk Trial sponsored by pharmaceutical company.
 
TOPICAL
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Methods Double-blind, placebo-controlled, randomised, phase III multicentre trial conducted in
the UK.
Length of follow-up (months): not reported
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=28) is reported in the main paper.
 
Participants 670 patients with newly diagnosed, pathologically confi rmed NSCLC; Stage IIIB or IV
disease; chemotherapy naive; no symptomatic brain metastases; deemed unsuitable
for chemotherapy because of poor ECOG PS (PS ≥2) or presence of several
comorbidities.
Inclusion criteria: newly diagnosed, pathologically confi rmed NSCLC; stage IIIb or IV
disease; chemotherapy naive; no symptomaticbrain metastases; deemed unsuitable
for chemotherapy because of poor ECOG PS (≥2) or presence ofseveral comorbidities
(including impaired renal functionwith creatinine clearance <60 mL/min), or
both;estimated life expectancy of at least 8 weeks;older than 18 years, diagnosis
Exclusion criteria; previous treatment with any biological anticancer therapy; previous
palliative radiotherapy (except to bone metastases, within the previous 2 weeks);
pregnant or lactating women; evidence of significant laboratory finding or concurrent
uncontrolled medical illness judged to potentially interfere with the trial treatment;
present treatment with a COX-2 inhibitor.
Median age: 77 years
Male:61.%
Ethnicity: 97% White
 
Interventions Treatment arm (17/350 patients EGFR M+): erlotinib 150mg/daily
Comparator arm (11/320 patients EGFR M+): placebo
 
Outcomes Primary:
OS
Secondary:
PFS, QoL, AEs
 
Mutation Assessment Method Sequenom OncoCarta Panel v1.0
 
Exons assessed 19,21
 
Notes The trial set out to assess the benefit sof erlotinib in a population of patients with
NSCLC who were considered unsuitable for chemotherapy
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Patients were randomised with a computer generated sequence with a
block size of 10.
 
Allocation concealment (selection
bias)
Low risk Randomisation was done by site staff telephoning theCancer Research
UK and University College London Cancer Trials Centre. All
investigators, clinicians, and patients were masked to assignment.
 
Blinding of participants and
personnel (performance bias)
Low risk All investigators, clinicians, and patients were masked to assignment.
Use of placebo.
 
Blinding of outcome assessment
(detection bias)
Low risk All investigators, clinicians, and patients were masked to assignment.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for. ITT analysis conducted.
 
Selective reporting (reporting bias) Low risk All specified outcomes reported.
 
Other bias Unclear risk Risk of patients in erlotinib arm developing rash thereby disclosing
treatment allocation. Partial funding from pharmaceutical company
 
TORCH
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Methods Open-label, randomised, phase III trial conducted in Italy and Canada.
Length of follow-up (months): 24.3
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=39) is presented as subgroup analysis in the primary publication.
 
Participants 760 patients with NSCLC
Inclusion Criteria: histologically or cytologically confirmed NSCLC Stage IIIB (with
malignant pleural effusion or supraclavicular nodes) or IV, at least one target or non-
target lesion age younger than 70 years (no age limits for Canadian centres), ECOG
PS 0 to 1. Patients at first diagnosis and those with recurrence after surgery were
eligible.
Exclusion Criteria: Prior treatment with anti-EGFR agents; history of prior invasive
malignancy or inadequate bone marrow, any unstable systemic disease, including
active infections and significant cardiovascular, hepatic, renal, or metabolic disease.
Patients with inflammatory eye surface changes and those who could not take or
absorb oral medications.
Median age: 62.5 years
Male:66.%
Ethnicity: 96% Caucasian
 
Interventions Treatment arm (19/380 patients EGFR M+): erlotinib 150 mg/daily until disease
progression
Comparator arm (20/380 patients EGFR M+): cisplatin 80 mg/m2 intravenously on day
1 and gemcitabine 1,200 mg/m2 intravenously per day on days 1 and 8 every 3 weeks
until progression.
 
Outcomes Primary Outcome:
OS
Secondary Outcomes:
Total progression-free survival (total PFS), time from random assignment to
progression after second-line treatment or death if it occurred before second
progression, or last follow-up visit for patients who were not included in the previous
two categories
PFS after first-line therapy (first PFS), defined as the time from random assignment to
progression after first-line treatment, or death if it occurred before first progression, or
last follow-up visit for patients who were not included in the previous two categories.
ORR, defined as the number of patients with complete or partial response at any time
divided by the total number of patients enrolled onto each arm.
All based on RECIST criteria.
Toxicity
 
Mutation Assessment Method Direct
 
Exons assessed 19
 
Notes Early trial termination due to the demonstration of the non-inferiority of the
experimental arm.
This was a two-stage trial with erlotinib given as first-line treatment and cisplatin plus
gemcitabine as second-line treatment.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Patients were centrally randomly assigned to the two treatment arms (1:1
ratio) through a centralized automated minimization procedure by using
histology (adenocarcinoma v other), smoking status (never v ever
smoker), sex, age (70 v70 years), centre, and PS (0 v 1) as strata.
 
Allocation concealment (selection
bias)
Low risk Centralised admin system used.
 
Blinding of participants and
personnel (performance bias)
High risk The trial was open-label.
 
Blinding of outcome assessment
(detection bias)
High risk No evidence of independent assessment.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for.
 
Selective reporting (reporting bias) Unclear
risk
Paper states that further secondary end points are not reported in this
article and included quality of life, comparisons of resource use, and
studies of exploratory biomarkers in tumor and blood samples.
 
Other bias High risk The trial was stopped early because non-inferiority of the experimental
arm was demonstrated. The trial was funded by a pharmaceutical
company.
 
WJTOG3405
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Methods Open-label, phase III randomised multi-centre trial conducted in Japan
Length of follow-up: 59.1 months
 
Participants 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with Stage
IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR
mutations. (Five patients were excluded after randomisation).
Inclusion Criteria: histologically or cytologically confirmed NSCLC, harbouring
activating EGFR mutations (either exon 19 deletion or L858R in exon 21), aged 75
years or younger, WHO PS 0–1, measurable or non-measurable disease and
adequate organ function.
Exclusion Criteria: previous drug therapy that had targeted EGFR, history of interstitial
lung disease, severe drug allergy, active infection or other serious disease condition,
symptomatic brain metastases, poorly controlled pleural effusion, pericardial effusion
or ascites necessitating drainage, active double cancer, or severe hypersensitivity to
drugs containing polysolvate 80.
Median age: 64 years
Male:36.%
Ethnicity: 100% Japanese
 
Interventions Treatment arm (86/86 patients EGFR M+): gefitinib 250 mg/daily
Comparator arm (86/86 patients EGFR M+): cisplatin 80 mg/m², IV over ¬90-min once
every 3 week cycle and docetaxel 60 mg/m², administered IV over 1 hr once every 3
week cycle
Treatment continued until progression of the disease, development of unacceptable
toxic effects, a request by the patient to discontinue treatment, serious non-compliance
with the protocol, or completion of three to six chemotherapy cycles. Further therapy
after progression of the disease was at the physician’s discretion.
 
Outcomes Primary Outcome:
PFS (RECIST criteria)
Secondary Outcomes:
OS,
ORR,
Disease Control Rate,
Safety,
 
Mutation Assessment Method PNA-LNA
 
Exons assessed 19,21
 
Notes All patients were EGFR M+
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Patients were allocated at the data centre to each treatment group using
a desktop computer programmed for the minimisation method.
 
Allocation concealment (selection
bias)
Low risk Centralised allocation see above
 
Blinding of participants and
personnel (performance bias)
High risk Open-label
 
Blinding of outcome assessment
(detection bias)
High risk No independent verification of PFS.
 
Incomplete outcome data (attrition
bias)
Low risk All patients accounted for.
 
Selective reporting (reporting bias) Low risk No concern over selective reporting.
 
Other bias Unclear risk 7 authors had received remuneration from pharmaceutical companies
including Astra Zeneca. The trial group is non-profit making but receives
unrestricted funding from several pharmaceutical companies
 
Yu 2014
Methods Open label, Phase II, single centre
Length of follow-up (months): 35
The trial included a mixed patient population. The analysis of EGFR M+ data only
(n=31) is presented as subgroup analysis in the primary publication.
 
Participants 117 chemo-naive patients with advanced (stage IIB or IV) non-squamous NSCLC.
ECOG 0 or 1.
Mean age=55
% Male= 50%
Ethnicity+ Chinese
 
Interventions Treatment arm (13/58 patients EGFR M+): gefitinib 250mg days 3 to 16 +pemetrexed
500mg/m2 with cisplatin 75mg/m2 or carboplatin AUC=5 every 3 weeks up to 6 cycles
Comparator arm (18/59 patients EGFR M+): pemetrexed 500mg/m2 with cisplatin
75mg/m2 or carboplatin AUC=5 every 3 weeks up to 6 cycles
 
Outcomes Primary outcome
Non-progression rate (RECIST 1.0)
Secondary outcomes
ORR
PFS
OS
AE
 
Mutation Assessment Method Direct sequencing
 
Exons assessed 18 to 21
 
Notes Treatment in both arms was administered for a amximum of 6 cycles
 
Risk of bias table
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Bias Authors' judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk No details given
 
Allocation concealment (selection
bias)
Unclear risk No details given
 
Blinding of participants and
personnel (performance bias)
High risk Open label trial
 
Blinding of outcome assessment
(detection bias)
High risk No evidence of independent radiological assessment
 
Incomplete outcome data (attrition
bias)
Unclear risk All patients accounted for
 
Selective reporting (reporting bias) Unclear risk Protocol not available but all stated outcomes are reported on
 
Other bias Unclear risk No other bias identified
 
Footnotes
AE: Adverse event
AFA: Afatinib
AUC: Area under the curve
CET: Cetuximab
CTX: Chemotherapy
DCR: Disease control rate
ECOG PS: Eastern Cooperative Oncology Group performance status
EGFR M+: Epidermal growth factor receptor mutation positive
ERL: Erlotinib
FACT-L: Functional Assessment of Cancer Therapy - Lung
FISH: Fluorescence In Situ Hybridisation
GEF: Gefitinib
HER:Human epidermal growth factor receptor
IHC: Immunohistochemistry
ITT: Intention to treat
IV: Intravenous
IVRS: Interactive voice response system
IWRS: Interactive web response system
MABs:Monoclonal antibody
NSCLC: Non-small cell lung cancer
ORR: Overall response rate
OS: Overall survival
PFS: Progression free survival
PS: performance status
QoL: Quality of life
RECIST: Response Evaluation on Solid Tumours
STA: Single technology appraisal
TTP: Time to progression
TTR:Time to treatment response
WHO: World Health Organisation
Characteristics of excluded studies 
Boutsikou 2013
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Reason for exclusion only patients surviving at 1 year were tested for EGFR mutation status
 
Crino 2008
Reason for exclusion EGFR expression tested only
 
ECOG 4508
Reason for exclusion Insufficient robust EGFR M+ samples available in trial
 
FASTACT
Reason for exclusion Data for the 7 EGFR patients not in usable format
 
Gatzemeier 2003
Reason for exclusion EGFR expression tested only
 
Goss 2009
Reason for exclusion EGFR expression tested only
 
Heigener 2014
Reason for exclusion The number of EGFR M+ patients was considered too small for analysis
 
Hirsh 2011
Reason for exclusion TKI used in both trial arms
 
Janne 2012
Reason for exclusion TKI used in both trial arms
 
JO25567
Reason for exclusion TKI used in both trial arms
 
Lilenbaum 2008
Reason for exclusion EGFR expression tested only
 
Massuti 2014
Reason for exclusion TKI used in both trial arms
 
NEJ005 2014
Reason for exclusion TKI used in both trial arms
 
NEJ009
Reason for exclusion TKI used in both trial arms
 
Rosell 2004
Reason for exclusion EGFR expression tested only
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Rosell 2008
Reason for exclusion EGFR expression tested only
 
Thatcher 2014
Reason for exclusion EGFR testing by IHC
 
White
Reason for exclusion Due to small sample size, survival analyses were not determined for patients with
EGFR mutations
 
Xie 2015
Reason for exclusion TKI used in both trial arms
 
Yang 2015
Reason for exclusion TKI used in both trial arms
 
Footnotes
Characteristics of studies awaiting classification 
INSPIRE
Methods Open-label, randomised, phase III, international trial
 
Participants 633 patients with previously untreated, stage IV, non-squamous NSCLC
 
Interventions Treatment arm (315 patients): necitumumab+pemetrexed and cisplatin
Comparator arm (318 patients):pemetrexed and cisplatin
Patients received either cisplatin 75 mg/m² and pemetrexed 500 mg/m² on day 1 of a
3-week cycle for a maximum of six cycles alone, or with necitumumab 800 mg on days
1 and 8. Necitumumab was continued after the end of chemotherapy until disease
progression or unacceptable toxic effects
 
Outcomes Primary outcome:
OS
Secondary outcomes:
TTP (RECIST criteria), ORR, Duration of Response, QoL, AEs
 
Notes Necitumumab continued to disease progression
 
TALENT
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Methods Placebo-controlled, randomised, phase III, international trial
 
Participants 1159 patients with histologically documented, unresectable, locally advanced,
recurrent or metastatic (Stage IIIb/IV) NSCLC, age 18 years, ECOG PS of 0 or 1;
 
Interventions Treatment arm (580 patients): erlotinib 150mg/daily plus cisplatin and gemcitabine
Comparator arm (579 patients): placebo plus cisplatin and gemcitabine
gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 of each
cycle.
Treatment up to 6 cycles
 
Outcomes Primary outcome:
OS
Secondary outcomes:
TTP (RECIST criteria), ORR, Duration of Response, QoL, AEs
 
Notes  
TRIBUTE
Methods Placebo-controlled, randomised, phase III multicentre trial conducted in the USA
 
Participants 1079 patients with histologically documented Stage IIIB or Stage IV NSCLC; age18
years; and ECOG PS of 0 or 1.
 
Interventions Treatment arm (539 patients): erlotinib 150mg/daily plus paclitaxel and carboplatin
Comparator arm (540 patients): placebo plus paclitaxel and carboplatin
Paclitaxel 200mg/m2 and carboplatin AUC 6 every 3 weeks until disease progression
 
Outcomes Primary outcome:
OS
Secondary outcomes:
TTP, ORR, AEs
 
Notes  
Footnotes
Characteristics of ongoing studies 
ARCHER
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Study name ARCHER
 
Methods Open-label, Phase III RCT conducted in Asia
 
Participants 440 Stage IIIB/IV NSCLC with at least one activating EGFR mutation.
 
Interventions Dacomitnib
Gefitinib
 
Outcomes Primary
PFS by independent radiological review
Secondary
PFS by investigator assessment, OS, ORR, duration of response, safety, QoL
 
Starting date April 2013
 
Contact information  
Notes Estimated Primary Completion Date: May 2015. ClinicalTrials.gov
Identifier:NCT01774721. http://clinicaltrials.gov/show/NCT01774721
 
Footnotes
Summary of findings tables
1 Summary of findings
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous, NSCLC
Patient or population: EGFR M+ patients with NSCLC
Settings: Oncology
Intervention: gefitinib
Comparison: paclitaxel + carboplatin
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of
Participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed
risk
Corresponding risk
[control] [experimental]
Overall survival 67 per 100 66 per 100 (58 to73)
HR 0.95 (0.77 to
1.18) 489 (2 studies) Moderate
For Asian
patients
Progression-free
survival 89 per 100
57 per 100 (50 to
65)
HR 0.39 (0.32 to
0.48) 485 (2 studies) Moderate
For Asian
patients
*The basis for the assumed risk is calculated as the event rate in the treatment group
The corresponding risk is calculated as the assumed risk x the relative risk (RR) of the intervention where RR = (1 - exp(HR
x ln(1 - assumed risk)) ) / assumed risk
CI: Confidence interval; RR: Risk Ratio; Hazard Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous, NSCLC
Patient or population: EGFR M+ patients with NSCLC
Settings: Oncology
Intervention: erlotinib
Comparison: control
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of
Participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed
risk
Corresponding risk
[control] [experimental]
Overall survival 56 per 100 54 per 100 (46 to63)
HR 0.95 (0.75,
1.22) 429 (3 studies) Moderate
Limited QOL - no
European patients
Progression-free
survival 73 per 100
34 per 100 (28 to
40)
HR 0.31 (0.25,
0.39) 595 (4 studies) Moderate
Limited QOL - no
European patients
*The basis for the assumed risk is calculated as the event rate in the treatment group
The corresponding risk is calculated as the assumed risk x the relative risk (RR) of the intervention where RR = (1 - exp(HR
x ln(1 - assumed risk)) ) / assumed risk
CI: Confidence interval; RR: Risk Ratio; HR: Hazard Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
3 Summary of findings
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous, NSCLC
Patient or population: EGFR M+ patients with NSCLC
Settings: Oncology
Intervention: afatinib
Comparison: CTX
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of
Participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed
risk
Corresponding risk
[control] [experimental]
Overall survival 46 per 100 44 per 100 (37 to52)
HR 0.93 (0.74 to
1.17) 709 (2 studies) High quality
For Asian
patients
Progression-free
survival 56 per 100
29 per 100 (15 to
50)
HR 0.41 (0.20 to
0.83) 709 (2 studies) High quality
For Asian
patients
*The basis for the assumed risk is calculated as the event rate in the treatment group
The corresponding risk is calculated as the assumed risk x the relative risk (RR) of the intervention where RR = (1 - exp(HR
x ln(1 - assumed risk)) ) / assumed risk
CI: Confidence interval; RR: Risk Ratio; HR: Hazard Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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Footnotes
Additional tables 
1 Adverse events - most commonly occurring Grade 3 & 4
Study Definition of
AE
Population Top AE (listed
according to
intervention)
Second top AE
(listed according to
intervention)
Third top AE (listed
according to
intervention)
Top 3 AEs (listed
according to
comparator)
AFATINIB TRIALS  
LUX-Lung 3 Grade >=3
CTC (V3)
AEs that were
reported in
>10% of
patients in
either group
and if there
was a >=10%
difference
between the
groups
EGFR only Rash/acne:
16.2% (AFA) vs 0%
(CTX)
Diarrhoea:
14.4% (AFA) vs 0%
(CTX)
 
Paronychia:
11.4% (AFA) vs 0%
(CTX)
Neutropenia: 18% vs
0.4%
Fatigue: 12.6% vs
1.3%
Leukopenia: 8.1% vs
0.4%
LUX-Lung 6 CTC (V3)
Events are
included if
reported for
>=1% of
patients in any
treatment
group
EGFR only Rash/acne:
14.6% (AFA) vs 0%
(CTX)
Diarrhoea:
5.4% (AFA) vs 0%
(CTX)
Stomatitis/mucositis:
5.4% (AFA) vs 0%
(CTX)
Neutropenia: 26.5%
vs 0.4%
Vomiting: 19.4% vs
0.8%
Leukopenia: 15.1%
vs 0.4%
ERLOTINIB TRIALS
CHEN Incidence rate
>=10%
Unselected
population
Rash:
64.9% (ERL) vs NR
(CTX)
Diarrhoea:
29.8% (ERL) vs NR
(CTX)
Mouth ulceration:
14% (ERL) vs NR
(CTX)
Decreased appetite:
26.3% vs NR
Diarrhoea: 12.3% vs
NR
Vomiting:
10.5% vs NR
Anorexia: 10.5% vs
NR
ENSURE
Grade ≥3
≥5% in either
arm
EGFR
Rash:
6.4% (ERL) vs 1%
(CTX)
Neutropenia,
Leukopenia
Anaemia:
All 0.9% (ERL) vs
25%, 14.4%, 12.5%
respectively (CTX)
 
 
Neutropenia:25% vs
0.9%
Leukopenia: 14.4%
vs 0.9%
Anaemia: 12.5% vs
0.9%
EURTAC Grade 3/4 CTC
(V3)
Common AEs
EGFR Rash:
13% (ERL) vs 0%
(CTX)
Fatigue:
6% (ERL) vs 20%
(CTX)
Diarrhoea:
5% (ERL) vs 0%
(CTX)
Neutropenia: 22% vs
0%
Fatigue: 20% vs 6%
Thrombocytopenia:
14% vs 0%
FASTACT 2 Grade 3/4 CTC
(V3)
Most
commonly
reported
Unselected
population
Neutropenia:
29% (ERL) vs 25%
(CTX)
Thrombocytopenia
14% (ERL) vs 14%
(CTX)
Anaemia:
11% (ERL) vs 9%
(CTX)
Neutropenia: 25% vs
29%
Thrombocytopenia:
14% vs 14%
Anaemia:9% vs 11%
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GTOWG Grade 3/4 Unselected
population
Rash:
12% (ERL) vs 0%
(CTX)
Diarrhoea:
6% (ERL) vs 2%
(CTX)
Constitutional
symptoms:
3% (ERL) vs 5%
(CTX)
Neutropenia: 36% vs
0%
Leukocytes: 33% vs
0%
Hemoglobin: 11% vs
0.7%
OPTIMAL Grade 3/4 CTC
(V3)
AEs occurred
in 3% or more
in either
treatment
group
EGFR Increased ALT:
4% (ERL) vs 1%
(CTX)
Skin rash:
2% (ERL) vs 0%
(CTX)
Diarrhoea:
1% (ERL) vs 0%
(CTX)
Neutropenia: 42% vs
0%
Thrombocytopenia:
40% vs 0%
Anaemia: 13% vs
0%
TOPICAL CTC (V3)
Specific AEs
grade 3 or 4
Unselected
population
Dyspnoea:
59% (ERL) vs 64%
(PLA)
Fatigue:
23% (ERL) vs 23%
(PLA)
Diarrhoea:
8% (ERL) vs 1%
(CTX)
Dyspnoea:
64% vs 59%
Fatigue:
23% vs 23%
Anorexia: 5% vs 5%
TORCH Worst toxicity
experienced
with first line
treatment
alone
Unselected
population
Skin Rash:
11% (ERL) vs 0%
(CTX)
Pulmonary toxicity:
9% (ERL) vs 6%
(CTX)
Fatigue:
8% (ERL) vs 12%
(CTX)
Neutropenia: 21% vs
0%
Thrombocytopenia:
12% vs 0%
Fatigue: 12% vs 8%
GEFITINIB TRIALS
 
FIRST-
SIGNAL
Grade 3 or 4
CTC (V3)
Unselected
population
Rash:
29.3% (GEF) vs 2%
(CTX)
Anorexia:
13.8% (GEF) vs
57.3% (CTX)
AST:
11.3% (GEF) vs 2%
(CTX)
Anorexia:57.3% vs
13.9%
Neuropenia: 54% vs
1.9%
Fatigue: 45.3% vs
10.1%
 
INTACT1
Grade 3/4 CTC
Commonly
occurring AEs
Unselected
Population
Thrombocytopenia:*
5.8% (GEF+CTX) vs
5.6% (CTX)
Rash:
3.6% (GEF+CTX)
vs 1.1% (CTX)
Diarrhoea:
3.6% (GEF+CTX) vs
2.3% (CTX)
 
Thrombocytopenia:*
5.6% vs 5.8%
Leukopenia: 2.5% vs
3.3%
Diarrhoea: 2.3% vs
3.6%
 
INTACT2
Grade 3/4 CTC
(V2)
Common drug-
related AEs
Unselected
population
Diarrhoea:
9.9% (GEF+CTX) vs
2.9% (CTX)
Neutropenia:
6.7% (GEF+CTX)
vs 5.9% (CTX)
Rash:
3.2% (GEF+CTX) vs
1.5% (CTX)
Neutropenia: 5.9%
vs 6.7%
Diarrhoea: 2.9% vs
9.9%
Vomiting: 2.3% vs
2%
 
IPASS
Grade 3,4 or 5
CTC (V3)
At least 10% of
patients in
either
treatment
group and at
least a 5%
difference
between arms
Unselected
population
Diarrhoea:
3.8% (GEF) vs 1.4%
(CTX)
Any neutropenia:
3.7% (GEF) vs
67.1% (CTX)
Rash:
3.1% (GEF) vs 0.8%
(CTX)
Any neutropenia:
67.1% vs 3.7%
Leukopenia: 35% vs
1.5%
Anaemia: 10.6% vs
2.2%
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NEJSG
Grade >=3
CTC (V3)
At least 10% of
patients in
either
treatment
group and at
least a 5%
difference
between arms
EGFR only  
ATE:
26.3% (GEF) vs
0.9% (CTX)
Rash:
5.3% (GEF) vs
2.7% (CTX)
 
Appetite loss:
5.3% (GEF) vs 6.2%
(CTX)
 
Neutropenia: 65.5%
vs 0.9%
Arthralgia: 7.1% vs
0.9%
Neuropathy: 6.2% vs
0%
Appetite loss: 6.2%
vs 5.3%
 
WJTOG3405
Grade >=3
CTC (V3)
AEs occurred
in 10% of
either of the
treatment
groups
EGFR only ALT/AST:
27.5% (GEF) vs
2.3% (CTX)
Rash:
2.3% (GEF) vs 0%
(CTX)
Fatigue:
2.3% (GEF) vs 2.3%
(CTX)
Neutropenia: 84% vs
0%
Leucocytopenia:
50% vs 0%
Anaemia: 17% vs
0%
Yu 2014
Grade 3+
Patients with at
least 1 AE
Unselected
population
Rash:
16% (GEF+CTX) vs
0% (CTX)
Vomiting:
10% (GEF) vs 8%
(CTX)
Neutropenia:
10% (GEF) vs 12%
(CTX)
Neutropenia: 12% vs
10%
Nausea: 8% vs 5%
Vomiting: 8% vs
10%
CETUXIMAB TRIALS          
BMS099
Grade 3/4 CTC
( V3)
Most frequent
and relevant
Grade 3/4 AEs
Unselected
population
Neutropenia:
62.5% (CET+CTX)
vs 56% (CTX)
Leukopenia:
43.8% (CET+CTX)
vs 30.7% (CTX)
Fatigue:
15.1% (CET+CTX)
vs 12.2% (CTX)
Same AEs as
intervention
FLEX
Grade 3/4 CTC
(V2)
AEs that were
reported in
>5% of
patients
(G3/G4) or
>1% (G4) or
AEs of special
interest in
either group
EGFR
expressing
Neutropenia:
53% (CET+CTX) vs
51% (CTX)
Leukopenia:
25% (CET+CTX)
vs 19% (CTX)
Febrile neutropenia:
22% (CET+CTX) vs
15% (CTX)
Neutropenia: 52%
(CTX) vs 52%
CET+CTX
Leukopenia: 19%
(CTX) vs 25% (CET
vs CTX)
Anaemia: 16%
(CTX) vs 1%
(CET+CTX)
Footnotes
AE= adverse event; AFA=afatinib; ATE=aminotransferase elevation; ALT=alanine aminotransferase; AST=aspartate
aminotransferase; CET=cetuximab; CTC=common toxicity criteria; CTX=cytotoxic chemotherapy; ERL=erlotinib;
GEF=gefitinib
*neutropenia was also reported as 5.8% for G3/4 as this rate was higher than the rate for all patients (5%) it was not included
in the table; ** Rash listed as Grades A to D rather than 3 or 4
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Other published versions of this review 
Classification pending references
Data and analyses 
1 Erlotinib versus Control
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Overall Survival 5   Hazard Ratio(IV, Random, 95% CI) Subtotals only
   1.1.1 Erlotinib versus CTX 3   Hazard Ratio(IV, Random, 95% CI) 0.95[0.75, 1.22]
   1.1.2 Erlotinib versus vinorelbine 1   Hazard Ratio(IV, Random, 95% CI) 2.16[0.58, 8.10]
   1.1.3 Erlotinib plus CTX versus
CTX plus placebo 1   Hazard Ratio(IV, Random, 95% CI) 0.48[0.27, 0.85]
1.2 Progression Free Survival 6   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   1.2.1 Erlotinib versus CTX 4   Hazard Ratio(IV, Fixed, 95% CI) 0.30[0.24, 0.38]
   1.2.2 Erlotinib versus vinorelbine 1   Hazard Ratio(IV, Fixed, 95% CI) 0.55[0.21, 1.46]
   1.2.3 Erlotinib plus CTX versus
CTX plus placebo 1   Hazard Ratio(IV, Fixed, 95% CI) 0.25[0.16, 0.39]
   1.2.4 Erlotinib versus CTX
(sensitivity analysis using ENSURE
independent review data)
4   Hazard Ratio(IV, Fixed, 95% CI) 0.33[0.26, 0.42]
1.3 Tumour response 7   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   1.3.1 Erlotinib versus CTX 5 593 Risk Ratio(M-H, Random, 95% CI) 2.20[1.53, 3.17]
   1.3.2 Erlotinib versus vinorelbine 1 24 Risk Ratio(M-H, Random, 95% CI) 0.83[0.19, 3.67]
   1.3.3 Erlotinib versus erlotinib plus
CTX 0 0 Risk Ratio(M-H, Random, 95% CI) Not estimable
   1.3.4 Erlotinib plus CTX versus
CTX plus placebo 1 97 Risk Ratio(M-H, Random, 95% CI) 5.74[2.86, 11.50]
2 Gefitinib versus CTX
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Overall survival 4   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   2.1.1 Gefitinib versus gemcitabine
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 1.04[0.50, 2.20]
   2.1.2 Gefitinib versus paclitaxel
plus carboplatin 2   Hazard Ratio(IV, Fixed, 95% CI) 0.95[0.77, 1.18]
   2.1.3 Gefitinib versus docetaxel
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 1.25[0.88, 1.78]
2.2 Progression free survival 4   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   2.2.1 Gefitinib versus gemcitabine
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 0.54[0.27, 1.10]
   2.2.2 Gefitinib versus paclitaxel
plus carboplatin 2   Hazard Ratio(IV, Fixed, 95% CI) 0.39[0.32, 0.48]
   2.2.3 Gefitinib versus docetaxel
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 0.49[0.34, 0.71]
2.3 Tumour response 4 648 Risk Ratio(M-H, Fixed, 95% CI) 1.87[1.60, 2.19]
   2.3.1 Gefitinib versus gemcitabine
plus cisplatin 1 42 Risk Ratio(M-H, Fixed, 95% CI) 2.26[1.17, 4.34]
   2.3.2 Gefitinib versus paclitaxel
plus carboplatin 2 489 Risk Ratio(M-H, Fixed, 95% CI) 1.83[1.54, 2.18]
   2.3.3 Gefitinib versus docetaxel
plus cisplatin 1 117 Risk Ratio(M-H, Fixed, 95% CI) 1.93[1.26, 2.94]
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3 Afatinib versus CTX
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
3.1 Overall survival 2   Hazard Ratio(IV, Fixed, 95% CI) 0.93[0.74, 1.17]
   3.1.1 Afatinib versus pemetrexed
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 0.91[0.66, 1.25]
   3.1.2 Afatinib versus gemcitabine
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 0.95[0.68, 1.33]
3.2 Progression free survival 2   Hazard Ratio(IV, Random, 95% CI) 0.41[0.20, 0.83]
   3.2.1 Afatinib versus pemetrexed
plus cisplatin 1   Hazard Ratio(IV, Random, 95% CI) 0.58[0.43, 0.78]
   3.2.2 Afatinib versus gemcitabine
plus cisplatin 1   Hazard Ratio(IV, Random, 95% CI) 0.28[0.20, 0.39]
3.3 Tumour response 2 709 Risk Ratio(M-H, Fixed, 95% CI) 2.71[2.12, 3.46]
   3.3.1 Afatinib versus pemetrexed
plus cisplatin 1 345 Risk Ratio(M-H, Fixed, 95% CI) 2.48[1.74, 3.54]
   3.3.2 Afatinib versus gemcitabine
plus cisplatin 1 364 Risk Ratio(M-H, Fixed, 95% CI) 2.92[2.08, 4.09]
4 Cetuximab plus CTX versus CTX
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
4.1 Overall survival 2   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   4.1.1 Cetuximab plus paclitaxel or
docetaxel plus carboplatin versus
paclitaxel or docetaxel plus
carboplatin
1   Hazard Ratio(IV, Fixed, 95% CI) 1.62[0.54, 4.84]
   4.1.2 Cetuximab plus vinorelbine
plus cisplatin versus vinorelbine plus
cisplatin
1   Hazard Ratio(IV, Fixed, 95% CI) 1.48[0.77, 2.82]
4.2 Progression free survival 2   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   4.2.1 Cetuximab plus paclitaxel or
docetaxel plus carboplatin versus
paclitaxel or docetaxel plus
carboplatin
1   Hazard Ratio(IV, Fixed, 95% CI) 1.17[0.36, 3.80]
   4.2.2 Cetuximab plus vinorelbine
plus cisplatin versus vinorelbine plus
cisplatin
1   Hazard Ratio(IV, Fixed, 95% CI) 0.92[0.53, 1.60]
4.3 Tumour response 2 81 Risk Ratio(M-H, Fixed, 95% CI) 1.43[0.83, 2.47]
   4.3.1 Cetuximab plus paclitaxel or
docetaxel plus carboplatin versus
paclitaxel or docetaxel plus
carboplatin
1 17 Risk Ratio(M-H, Fixed, 95% CI) 4.50[0.63, 32.38]
   4.3.2 Cetuximab plus vinorelbine
plus cisplatin versus vinorelbine plus
cisplatin
1 64 Risk Ratio(M-H, Fixed, 95% CI) 1.19[0.67, 2.11]
5 Erlotinib versus CTX
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
5.1 Overall survival 3   Hazard Ratio(IV, Fixed, 95% CI) 0.96[0.75, 1.23]
   5.1.1 Erlotinib versus gemcitabine
plus cisplatin 2   Hazard Ratio(IV, Fixed, 95% CI) 1.00[0.71, 1.40]
   5.1.2 Erlotinib versus docetaxel
plus cisplatin or gemcitabine plus
cisplatin
1   Hazard Ratio(IV, Fixed, 95% CI) 0.91[0.63, 1.31]
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5.2 Progression free survival 4   Hazard Ratio(IV, Fixed, 95% CI) 0.29[0.24, 0.35]
   5.2.1 Erlotinib versus gemcitabine
plus carboplatin 2   Hazard Ratio(IV, Fixed, 95% CI) 0.24[0.18, 0.33]
   5.2.2 Erlotinib versus gemcitabine
plus cisplatin 1   Hazard Ratio(IV, Fixed, 95% CI) 0.60[0.30, 1.19]
   5.2.3 Erlotinib versus docetaxel
plus cisplatin or gemcitabine plus
cisplatin
1   Hazard Ratio(IV, Fixed, 95% CI) 0.34[0.23, 0.50]
   5.2.4 Erlotinib versus gemcitabine
plus carboplatin (sensitivity analysis
using ENSURE independent review
data)
2   Hazard Ratio(IV, Fixed, 95% CI) 0.27[0.19, 0.37]
5.3 Tumour response 5 593 Risk Ratio(M-H, Fixed, 95% CI) 2.26[1.85, 2.76]
   5.3.1 Erlotinib versus gemcitabine
plus carboplatin 2 371 Risk Ratio(M-H, Fixed, 95% CI) 2.05[1.65, 2.56]
   5.3.2 Erlotinib versus gemcitabine
plus cisplatin 1 39 Risk Ratio(M-H, Fixed, 95% CI) 1.68[0.67, 4.24]
   5.3.3 Erlotinib versus docetaxel
plus cisplatin or gemcitabine plus
cisplatin
1 173 Risk Ratio(M-H, Fixed, 95% CI) 3.89[2.28, 6.63]
   5.3.4 Erlotinib versus vinorelbine
plus carboplatin 1 10 Risk Ratio(M-H, Fixed, 95% CI) 0.33[0.04, 2.56]
6 Erlotinib plus CTX versus CTX plus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
6.1 Overall Survival 1   Hazard Ratio(IV, Fixed, 95% CI) 0.48[0.27, 0.85]
   6.1.1 Erlotinib plus gemcitabine
plus carboplatin or cisplatin versus
gemcitabine plus carboplatin or
cisplatin plus placebo
1   Hazard Ratio(IV, Fixed, 95% CI) 0.48[0.27, 0.85]
6.2 Progression Free Survival 1   Hazard Ratio(IV, Fixed, 95% CI) 0.25[0.16, 0.39]
   6.2.1 Erlotinib plus gemcitabine
plus carboplatin or cisplatin versus
gemcitabine plus carboplatin or
cisplatin plus placebo
1   Hazard Ratio(IV, Fixed, 95% CI) 0.25[0.16, 0.39]
6.3 Tumour response 1 97 Risk Ratio(M-H, Fixed, 95% CI) 5.74[2.86, 11.50]
   6.3.1 Erlotinib plus gemcitabine
plus carboplatin or cisplatin versus
gemcitabine plus carboplatin or
cisplatin plus placebo
1 97 Risk Ratio(M-H, Fixed, 95% CI) 5.74[2.86, 11.50]
7 Erlotinib versus vinorelbine
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
7.1 Overall survival 1   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   7.1.1 Erlotinib versus vinorelbine 1   Hazard Ratio(IV, Fixed, 95% CI) 2.16[0.58, 8.10]
7.2 Progression free survival 1   Hazard Ratio(IV, Fixed, 95% CI) Subtotals only
   7.2.1 Erlotinib versus vinorelbine 1   Hazard Ratio(IV, Fixed, 95% CI) 0.55[0.21, 1.46]
7.3 Tumour response 1   Risk Ratio(M-H, Fixed, 95% CI) Subtotals only
   7.3.1 Erlotinib versus vinorelbine 1 24 Risk Ratio(M-H, Fixed, 95% CI) 0.83[0.19, 3.67]
8 Gefitinib plus CTX versus CTX
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
8.1 Progression-free survival 1   Hazard Ratio(IV, Fixed, 95% CI) 0.20[0.05, 0.75]
8.2 Tumour response 1 31 Risk Ratio(M-H, Fixed, 95% CI) 1.54[0.89, 2.67]
Figures
Figure 1
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Caption
Study flow diagram.
Figure 2
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Caption
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included
studies.
Figure 3
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Caption
Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
Sources of support 
Internal sources
No sources of support provided
External sources
No sources of support provided
Feedback 
Appendices 
1 MEDLINEedline (via OvidVID; 1946 onwards)
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1 exp Carcinoma, Non-Small-Cell Lung/
2 (lung and (cancer$ or carcin$ or neoplasm$ or tumour$ or tumor$) and ((non-small or nonsmall) and cell)).ti,ab.
3 (erlotinib or tarceva).af.
4 (gefitinib or iressa).af.
5 (tyrosine kinase inhibit$ or monoclonal antibod$ or EGFR).tw.
6 1 or 2
7 or/3-5
8 6 and 7
9 randomized controlled trial.pt.
10 controlled clinical trial.pt.
11 randomized.ab.
12 placebo.ab.
13 clinical trials as topic.sh.
14 randomly.ab.
15 trial.ti.
16 or/9-15
17 exp animals/ not humans.sh.
18 16 not 17
19 8 and 18
2 Updated search strategy
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell
lung càncer
(date: Feb 5th, 2014)
Ovid MEDLINE(R) <1946 to January Week 4 2014>
1 exp Carcinoma, Non-Small-Cell Lung/ (30107)
2 (lung and (cancer$ or carcin$ or neoplasm$ or tumour$ or tumor$) and ((non-small or nonsmall) and cell)).ti,ab. (29454)
3 nsclc.ti,ab. (16188)
4 1 or 2 or 3 (36222)
5 (tyrosine kinase inhibit$ or monoclonal antibod$ or EGFR or TKI$).tw. (183400)
6 (erlotinib or tarceva).af. (3081)
7 (gefitinib or iressa).af. (3928)
8 (afatinib or gilotrif).af. (65)
9 5 or 6 or 7 or 8 (185552)
10 4 and 9 (5109)
11 randomized controlled trial.pt. (359493)
12 controlled clinical trial.pt. (86909)
13 randomized.ab. (260696)
14 placebo.ab. (141221)
15 drug therapy.fs. (1651531)
16 randomly.ab. (186387)
17 trial.ab. (268187)
18 groups.ab. (1203305)
19 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (3092194)
20 exp animals/ (16958091)
21 humans.sh. (13090537)
22 20 not 21 (3867554)
23 19 not 22 (2628643)
24 10 and 23 (3449)
25 10 and 23 (3449)
26 limit 25 to yr="2012 -Current" (760)
Ovid Embase <1996 to 2014 February 14>
1 exp lung non small cell cancer/ (55263)
2 (lung and (cancer$ or carcin$ or neoplasm$ or tumour$ or tumor$) and ((non-small or nonsmall) and cell)).ti,ab. (44493)
3 nsclc.ti,ab. (29792)
4 1 or 2 or 3 (62940)
5 (tyrosine kinase inhibit$ or monoclonal antibod$ or EGFR or TKI$).tw. (152359)
6 (erlotinib or tarceva).af. (15970)
7 (gefitinib or iressa).af. (15976)
8 (afatinib or gilotrif).af. (707)
9 5 or 6 or 7 or 8 (166496)
10 4 and 9 (14716)
11 random:.tw. or placebo:.mp. or double-blind:.mp. (900038)
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small c...
73 / 73
12 10 and 11 (2814)
13 10 and 11 (2814)
14 limit 13 to yr="2012 -Current" (765)
Cochrane Central Register of Controlled Trials : Issue 1 of 12, January 2014
#1MeSH descriptor: [Carcinoma, Non-Small-Cell Lung] explode all trees2303
#2lung:ti,ab 18465
#3(cancer* or carcin* or neoplasm* or tumour* or tumor*):ti,ab 69595
#4(non-small or nonsmall):ti,ab 4068
#5#2 and #3 and #4 4012
#6nsclc:ti,ab 2450
#7#1 or #5 or #6 4416
#8(tyrosine kinase inhibit* or monoclonal antibod* or EGFR or TKI*):ti,ab 3127
#9(erlotinib or tarceva):ti,ab 245
#10(gefitinib or iressa):ti,ab 213
#11(afatinib or gilotrif):ti,ab 19
#12#8 or #9 or #10 or #11 3406
#13#7 and #12 399
#14#7 and #12 from 2012 to 2014135
3 Search strategy 3
Ovid EMBASE April 2014 until 1st June 2015 and 1946 to 1st June
1 exp lung non small cell cancer
2 (lung and (cancer$ or carcin$ or neoplasm$ or tumour$ or tumor$) and ((non-small or nonsmall) and cell)).ti,ab.
3 nsclc.ti,ab.
4 1 or 2 or 3
5 (tyrosine kinase inhibit$ or monoclonal antibod$ or EGFR or TKI$).tw.
6 (erlotinib or tarceva).af.
7 (gefitinib or iressa).af.
8 (afatinib or gilotrif).af.
9 5 or 6 or 7 or 8
10 4 and 9
11 random:.tw. or placebo:.mp. or double-blind:.mp.
12 10 and 11
